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Spurred by treble damages, substantial penalties, and lucrative relator awards, 
litigation under federal and state False Claims Act (“FCA”) statutes has exploded in 
recent years.  Much of that explosion stems from aggressive and creative legal 
theories that challenge controversial industry practices or even well-known 
loopholes or waste in government policy.  Evidence from governmental entities can 
be critically important in litigating these FCA claims.  Unique aspects of False 
Claims Act actions, however, can aggravate the risk of losing this important 
evidence, leaving the parties, judges, and juries without the evidentiary record 
necessary to equitably adjudicate these disputes.  Defendants can face the risk of 
treble damages, substantial penalties, or worse without the opportunity to build their 
defense before evidence is destroyed. Calling on his first-hand experience litigating 
FCA cases, the author highlights the risk of government spoliation in FCA cases and 
provides recommendations for courts and counsel to address this escalating 
problem. 
I.  INTRODUCTION  
On a near-daily basis, the legal press brings word of a new, novel theory of 
liability under the False Claims Act (“FCA”), a federal law imposing liability on 
persons and companies who defraud the government.  In this environment, alleged 
malfeasance with any feasible connection to government funds could invite exposure 
to treble damages, substantial statutory penalties, or worse under the FCA and its 
state law companions.  Government contractors face potential FCA liability on all 
matters of contractual disputes, including those related to the costs of shipping, 
feeding overseas troops, the pricing for computer software, and providing 
nonconforming parts to the military.1  Banks face FCA claims ranging from alleged 
failures to follow mortgage approval standards to assertions that inflated foreign 
exchange rates defrauded pension funds.2  Pharmaceutical and medical device 
                                                          
 1 See, e.g., Helen Christophi, UPS Worker Defends FCA Claims In Shipping Overcharge 
Suit, LAW360.COM (Feb. 20, 2013), http://www.law360.com/articles/417034/ups-worker-
defends-fca-claims-in-shipping-overcharge-suit; see, e.g., Bibeka Shrestha, US Highlights 
KBR Kickbacks In $41M Contract Fight, LAW360.COM (Feb. 2, 2012), http://www.law360. 
com/articles/305333/us-highlights-kbr-kickbacks-in-41m-contract-fight; see, e.g., Erin Fuchs, 
US Appeals Relators’ $8M Share Of $48M Cisco FCA Deal, LAW360.COM (Nov. 14, 2011), 
http://www.law360.com/articles/285596/us-appeals-relators-8m-share-of-48m-cisco-fca-deal; 
see, e.g., Keith Goldberg, Oracle To Pay Record $200M To End Software FCA Suit, LAW360. 
COM (Oct. 6, 2011), http://www.law360.com/articles/276624/oracle-to-pay-record-200m-to-
end-software-fca-suit; see, e.g., Megan Stride, Kaman To Pay $4.8M To End False Claims 




 See, e.g., Lana Birbrair, Citi Closes Door on DOJ’s Reckless-Mortgage Suit for $158M, 
LAW360.COM (Feb. 15, 2012), http://www.law360.com/articles/310131/citi-closes-door-on-
doj-s-reckless-mortgage-suit-for-158m; see, e.g., Keith Goldberg, BNY Mellon Can’t Shake 
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manufacturers face myriad FCA allegations, from promoting the “off-label” use of 
drugs and misreporting drug prices to alleged violations of FDA regulations in 
connection with securing drug approvals and misrepresenting the efficacy of drugs.3  
Even alleged recruiting violations and misstatements in accreditation certifications 
by educational institutions can give rise to FCA claims.4  And these are just a 
handful of seemingly endless possibilities.     
The FCA promotes new targets and theories with substantial financial awards for 
those who formulate them.  FCA actions are typically filed in the first instance by 
private citizen “relators”—often former corporate employees or other “industry 
insiders”—who stand to recover 15 to 30% of any recovery.5  The risks posed by 
treble damages, substantial penalties, and threats of exclusion from government 
programs or criminal liability has led to breathtaking settlements in recent years that 
run into the hundreds of millions and even billions of dollars.  With these monetary 
incentives, recent pro-plaintiff amendments to the FCA, and an increased willingness 
by many courts to expand the FCA’s reach, there is little reason to expect a recession 
in what some have called the “fastest growing area of federal litigation.”6  
The FCA’s rampant expansion has been well chronicled.  But unique challenges 
presented by this expansion in the actual litigation setting—including the 
                                                          




 See, e.g., Gavin Broady, Maryland AG Hits GSK With Avandia False Claims Suit, (Feb. 
21, 2013), LAW360.COM, http://www.law360.com/lifesciences/articles/417188?nl_pk=73bc67 
51-854f-4e1b-b0b7-c14b2c3fb270&utm_source=newsletter&utm_medium=email&utm_camp 
aign=lifesciences; see, e.g., Daniel Wilson, Warner Chilcott Falsely Promoted Drugs, FCA 
Suit Says, LAW 360.COM (Feb. 22, 2013), http://www.law360.com/health/articles/418015?nl_ 
pk=6078e50c-0f0a-4b00-aabb-bf91df385cfd&utm_source=newsletter&utm_medium=email& 
utm_campaign=health; see, e.g., Rachel Slajda, J&J To Pay $1B To Settle Risperdal Civil 
Claims: Report, LAW360.COM (Jan. 5, 2012), http://www.law360.com/articles/297732/j-j-to-
pay-1b-to-settle-risperdal-civil-claims-report; see, e.g., Richard Vanderford, Drug Co. Dava 
Pays $11M To End Medicaid Rebate Suit, LAW 360.COM (Feb. 8, 2012), http://www.law360. 
com/articles/307884/drug-co-dava-pays-11m-to-end-medicaid-rebate-suit; see, e.g., Roxanne 





 See, e.g., Brian Mahoney, 9th Circ. Reinstates Kaplan FCA Suit Over Fake Enrollm-
ents, LAW360.COM (Feb. 14, 2013), http://www.law360.com/articles/415383/9th-circ-rein 
states-kaplan-fca-suit-over-fake-enrollments; see, e.g., Rachel Slajda, DOJ Pans For-Profit 
College Co.’s Bid To Nix Fraud Suit, LAW360.COM (Dec. 8, 2011), http://www.law360.com 
/articles/291748/doj-pans-for-profit-college-co-s-bid-to-nix-fraud-suit; see, e.g., Abigail 




 Joseph P. Giffith, Jr., Guide to Federal False Claims Act (FCA) for Whistleblower & 
Qui Tam Plaintiffs & Their Lawyers, AVVO.COM, http://www.avvo.com/legal-guides/ugc/high 
lights-of-the-federal-false-claims-act-fca-for-whistleblowersqui-tam-plaintiffs--lawyers (last 
visited April 26, 2013).  
 
6
 ABA CLE Program Guide, The Eighth Annual National Institute on the Civil False 
Claims Act and Qui Tam Enforcement (June 2-4, 2010), available at http://new.abanet.org 
/calendar/civil-false-claims-act-and-qui-tam-enforcement-2010/Documents/cen0cfc_Websi 
te_Brochure_5-7-10.pdf. 
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preservation of evidence—have been largely underappreciated and unresolved.  
Many of today’s largest FCA cases involve established industry practices or 
controversial government reimbursement policies.  Other cases turn on the 
interpretation of rules and regulations drafted by government agencies or contracts 
negotiated with government officials.  Nearly all involve a fact-intensive inquiry into 
the monetary impact of allegedly false or fraudulent claims, statements, or conduct 
on government expenditures.  It should come as no surprise, then, that data, 
documents, and testimonial evidence from government entities could be very 
relevant in these types of FCA actions.  Unique aspects of FCA cases, however, 
aggravate the risk that this evidence may be lost, creating an unbalanced playing 
field where the government and relators can gather fresh evidence while defendants 
are left, often years later, to pick through stale evidentiary scraps.  
This Article explores the peculiar dilemma of spoliation in FCA cases.  Section I 
traces the FCA’s evolution from the relatively unused “Informer’s Law” to the 
powerful force that it and state law FCA statutes have become today.  Section II 
highlights the growing importance of evidence from government entities in the types 
of FCA cases being litigated today.  Section III discusses the particular challenges 
faced in FCA cases to preserving an adequate factual record.  Section IV concludes 
with recommendations to courts and practitioners to help mitigate these challenges. 
II.  CAPTAINING THE FALSE CLAIMS ACT INTO UNCHARTED WATERS  
A.  The Explosion of the False Claims Act 
Originally known as the “Informer’s Law,” the FCA was enacted during the Civil 
War as a vehicle for prosecuting suppliers of shoddy war supplies, such as passing 
sand for gun powder.7  Under the original law, defendants were subjected to double 
damages, as well as civil and criminal penalties, and whistleblower “relators” could 
receive up to half of any damages or penalties awarded in the action.8  Partially 
because of legal amendments enacted in 1943 to limit parasitic suits and decrease the 
monetary awards to relators, however, the FCA fell into relative obscurity over the 
next century.9   
This began to change in 1986, when Congress repealed certain of the earlier 
amendments and increased the relator’s award and statutory penalties available 
under the False Claims Act.10  Over the last two decades, the FCA has become the 
government’s primary weapon of combating fraud against the government.  The 
numbers tell a remarkable story.  In 1987, only 30 new qui tam suits were initiated 
                                                          
 
7
 See Joan H. Krause, Health Care Providers and the Public Fisc: Paradigms of 
Government Harm Under the Civil False Claims Act, 36 GA. L. REV. 121, 125, 129 (2001). 
 
8
 Edward P. Lansdale, Use as Directed?  How Prosecutors Are Expanding the False 




 See id; see Congressional Research Service, Qui Tam: The False Claims Act and 
Related Federal Statutes (Aug. 6, 2009), available at http://www.fas.org/sgp/crs/misc/R4 
0785.pdf (discussing the historical development of the FCA). 
 
10
 Lansdale, supra note 8, at 169-70. The 1986 amendments increased the penalty from 
$2,000 to $5,000 to $10,000 (now $5,500 to $11,000) for each FCA violation, provided for 
treble damages, and increased the relator’s award from 15 to 30 percent of the government’s 
recovery.  31 U.S.C. § 3729(a)(1); 31 U.S.C. § 3730(d)(2). 
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under the FCA.11  By 1997, that number had increased to 547.12  In 2011, 638 new 
qui tam suits were filed and nearly $3 billion was collected through settlements and 
judgments; two-thirds of the recoveries related to the healthcare industry alone.13  
All told, since 1987, over $30 billion has been collected through FCA settlements or 
judgments.14  Actions are proliferating rapidly under state FCA statute, as well.  
Spurred by federal incentives, twenty-nine states and eleven municipalities, 
including the District of Columbia, have now enacted state False Claims Act 
statutes.15  
In short, state and federal FCA claims have become big business for state and 
local governments, relators, and their attorneys.  Recent amendments to the FCA, 
further strengthening the plaintiff’s hand, promise only to expand their use.16 
B.  Novel and Expansive Legal Theories Continue to Emerge 
FCA actions have traditionally focused on allegations like “double-billing,” 
billing for services or products never provided or delivered, “upcoding” healthcare 
services to gain a higher reimbursement rate, performing inappropriate or 
unnecessary medical care, “unbundling” of services required by program rules to be 
“bundled” into one reimbursement rate, and billing at doctor rates for services 
provided by nurses or interns.17  Such claims continue in full force today.    
In recent years, however, relators and government prosecutors have looked to 
expand the FCA’s reach, often beyond the entities or individuals who actually 
submitted claims to those who allegedly “caused” others to submit “false or 
fraudulent” claims.18  In many cases, these efforts involve employing the FCA to 
                                                          
 
11
 Civil Div., U.S. Dep’t of Justice, Fraud Statistics, Oct. 1, 1987-Sept. 30, 2011, 












 States With False Claims Acts, TAF.ORG, available at http://www.taf.org/states-false-
claims-acts (last visited April 26, 2013). States that pass laws meeting certain federal stand-
ards are entitled to receive an additional 10% of any recoveries of federal Medicaid funds 
recovered through litigation filed by the state.  see 42 U.S.C. § 1396h; see also State False 
Claims Act Reviews, OIG.HHS.GOV, available at http://oig.hhs.gov/fraud/falseclaimsact.asp; 
Publication of OIG’s Guidelines for Evaluating State False Claims Acts, 71 Fed. Reg. 48, 552 
(Aug. 21, 2006).   
 
16
 See R. Christopher Cook, Nolan S. Young, Lee Perla, Heather O’Shea, Stephen G. 
Sozio, Frank E. Sheeder III, Suzanne C. Jones, Martha Boersch, Fraud Enforcement Recovery 
Act of 2009 Becomes Law, Expanding Exposure Under the False Claims Act and Funding 
Anti-Fraud Enforcement, JONESDAY.COM, June 2009, available at http://www.jonesday.com/ 
fraud-enforcement-recovery-act-of-2009-becomes-law-expanding-exposure-under-the-false-
claims-act-and-funding-anti-fraud-enforcement-06-03-2009 (discussing the impact of the 
amendments to the FCA implemented by FERA).  
 
17
 See False Claims Act Overview,TAF.ORG, available at http://www.taf.org/resource/fca 
/false-claims-act-overview (last visited April 6, 2013). 
 
18
 See FY 2012 Is Record Year for FCA Recoveries, TAF.ORG, available at  http://taf.org/ 
blog/fy-2012-record-year-fca-recoveries (last visited April 26, 2013); FY 2011 False Claims 
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correct perceived, yet politically sensitive, imperfections in government 
reimbursement policies.  For example, one commentator observed: 
[H]ealth care fraud enforcement offers significant advantages to the 
government.  [E]nforcement may achieve a quicker “fix” to a problem 
than would be possible in the legislative or regulatory arenas.  If those 
processes have failed to resolve the issue--as with Medicare drug 
reimbursement, for example--prosecutors may regard enforcement as the 
only practical method of achieving the “right” result.  When politics and 
inertia stymie the development of necessary regulations, litigation 
provides an alternative.19 
Another commentator stated that FCA “[l]itigation may also reflect the 
government’s desire to recapture ‘overpayments’ that, because of the political 
bargains that underlie Medicare and Medicaid, are not available through ex ante 
regulation.”20  The FCA can even allow the government to have its cake and eat it 
too, permitting it to recoup “overpayments” from parties who neither submitted nor 
received payments on claims, while maintaining the allegedly “false”—yet 
politically sensitive—level of payment to those who submitted the claims. 
Some would argue that the practices or payments being challenged in more novel 
FCA cases represent, at best, government waste, not any effort to defraud the 
                                                          




 Joan H. Krause, Regulating, Guiding, and Enforcing Health Care Fraud, 60 N.Y.U. 
ANN. SURV. AM. L. 241, 269 (2004); see also Krause, supra note 7, at 125 (“The FCA initially 
was applied in straightforward cases of fraud, such as physicians who billed the government 
for services they never performed. But gradually, more creative theories have emerged. Since 
the mid-1990’s, the FCA has been used in situations when health care services were in fact 
provided to patients, but where the defendants may have violated underlying legal 
requirements in furnishing those services, such as federal anti-referral laws. These cases signal 
the government’s willingness to invoke the FCA against activities that are increasingly far 
removed from traditional types of government procurement fraud – a controversial position in 
light of the fact that the majority of FCA cases are resolved through settlement rather than 
trial.”(citations omitted)).   
 
20
 William M. Sage, Unfinished Business: How Litigation Relates to Health Care 
Regulation, 28 J. HEALTH POL. POL’Y & L. 387, 411 (2003); see also Patric Hooper, Health 
Care Fraud Frenzy: An Exercise in Overzealous Law Enforcement, 1 HEALTH CARE FRAUD 
REP. (BNA) 799, 799 (Nov. 19, 1997) (“Rather than making the kind of hard, and often 
politically unpopular, decisions . . . such as rationing health care or increasing costs to 
beneficiaries, politicians have embraced the politically popular notion that rising health care 
costs are due primarily to rampant fraud in the health care industry.”); see also United States 
v. NHC Healthcare Corp., 115 F. Supp.2d 1149, 1152 (W.D. Mo. 2000) (remarking on the 
government’s more expansive use of the FCA, the court stated that “ [a]lthough extensive 
regulatory authority exists for punishing unscrupulous facilities, the Government has 
increasingly opted for the expedited results of lawsuits under the FCA’s powerful threats of 
significant fines, treble damages, and costly litigation fees.  The health care industry has 
vigorously resisted this movement by the Justice Department on a variety of fronts, not the 
least of which is that the FCA was never intended to be a regulatory tool. . . .  Until this issue 
works its way through the appellate system it will remain unclear whether the Government’s 
movement towards increased scrutiny of care facilities through FCA lawsuits is a bona fide 
exercise of prosecutorial resources or an improper expansion of this powerful Act.”). 
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government.21  Nonetheless, any link between an alleged regulatory violation or 
disfavored industry practice and a request for government funds, may prompt 
relators and government prosecutors to create a new FCA theory.  Many of these 
legal theories are left unproven, as the mere risk of draconian damages, penalties, 
and exclusion from government programs can force settlements.22   
Regardless of how one views the merits of the FCA’s expansion, there is little 
reason to expect a change in direction.  In the last three years, the DOJ has 
established numerous teams and task forces to raise the stakes on alleged fraud.23  
These teams face mounting expectations, as government recoveries over the last few 
years have set an enormously high bar.  Sustaining such recoveries will require new 
legal theories and new targets, which predictably will include a continued focus on 
policy imperfections and loopholes that have long vexed regulatory officials.   
III.  THE HEIGHTENED IMPORTANCE OF EVIDENCE FROM GOVERNMENT ENTITIES 
In traditional FCA cases, factual disputes typically focused on the defendant’s 
conduct and state of mind.  Evidence from the government’s files and witnesses 
typically carried little importance.  But the situation can be altogether different in 
many of today’s high-stakes FCA cases, particularly those that challenge sensitive 
reimbursement policies.   
Evidence sought from government entities and witnesses is often referred to—in 
some cases inaptly—as “government knowledge” evidence.24  This terminology is 
                                                          
 
21
 See Congressional Budget Office, Statement of Paul N. Van de Water, Assistant 
Director Budget Analysis Division Congressional Budget Office, before the Committee on 
Finance United States Senate, Fraud, Waste and Abuse in Medicare (July 31, 1995) (finding 
“no clear line separates abusive activities from fraud.”). 
 
22
 See, e.g., Krause, supra note 7, at 126-27 (noting “[w]ithin the industry, there is a 
growing concern that the Act’s large penalties may force health care providers to settle cases 
that could not be proven in court, such as allegations of falsity stemming from good faith 
interpretations of ambiguous regulations.  While settlement is an efficient way to dispose of 
FCA allegations, it also removes crucial legal issues from judicial scrutiny-including the 
falsity of the claim and the defendant’s fraudulent intent.” (citations omitted)); Robert Salcido, 
Recent False Claims Act Prosecutions Fall Flat: Did Previous Large Settlements in FCA 
Cases Result from Rampant Abuse or Government Leverage?, NAT'L L.J., at S1-S2 (July 4, 
2005) (stating defense lawyers “assert that the government’s recoveries typically reflect not 
the strength of the government’s case but the lever it possesses under its ability to exclude 
companies from participation in Medicare if they are defeated at trial”). 
 
23
 Attorney General Eric Holder, U.S. Dep’t of Justice, Remarks on New Medicare Fraud 
Initiative at a Press Conference with HHS Secretary Sebelius (May 20, 2009) (transcript 
available at http://www.justice.gov/ag/speeches/2009/ag-speech-090520.html); Financial 
Fraud Enforcement Task Force, About the Task Force, STOPFRAUD.GOV, available at 
http://www.stopfraud.gov/about.html (last visited April 6, 2013). 
 
24
 United States’ and Relator’s Memorandum in Support of Their Motion for a 
Comprehensive Case Management Order at 7-10, Dkt. No. 3108, In re Pharm. Indus. Average 
Wholesale Price Litig., MDL 1456 Civ. Action No. 01-CV-12257-PBS (D. Mass. Sept. 15, 
2006) (attempting to stay discovery against government officials under the notion that it 
would not be relevant to a “government knowledge” defense); Hearing Transcript, In re 
Pharm. Indus. Average Wholesale Price Litig., MDL 1456 Civ. Action No. 01-CV-12557-
PBS (Oct. 26, 2006) at 14 (defense attorney:  “[T]the point I’m trying to make is that this isn’t 
about government knowledge.  It’s about government policy.”); id. (denying government’s 
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partially a historical artifact.  Prior to the FCA’s 1986 amendments, the 
government’s prior knowledge of the facts—government knowledge—underlying a 
qui tam suit formed an affirmative defense barring the claim.25  The 1986 
amendments, however, removed that jurisdictional bar and replaced it with the more 
forgiving “public disclosure” bar; this meant the government’s prior knowledge of 
the underlying facts was not an “automatic bar” to the suit.26  The 1986 amendments 
did not mean, however, that the government’s knowledge would now be irrelevant to 
the FCA claims.  Instead, the 1986 amendments “le[ft] open what would be the 
effect of government knowledge of the facts underlying the suit.”27   
Although government knowledge of the underlying facts no longer serves as an 
automatic bar to a suit, courts, litigants, and commentators often still employ the 
government knowledge nomenclature to generally describe evidence from 
government entities and witnesses.  This can create confusion about the 
discoverability and admissibility of evidence from government entities.  Often, 
defendants are not seeking to discover or introduce this evidence solely, or even 
primarily, in connection with a strict government knowledge affirmative defense.  
Rather, as discussed below, evidence from government entities can also be relevant 
to, among other things, challenging the fundamental elements of plaintiff’s FCA 
claim (falsity, scienter, causation, materiality, and damages) and, of course, the 
public disclosure. 
Courts recognize that evidence from government entities may be highly relevant 
to scienter in FCA cases.28  This would include, for example, evidence of situations 
where the defendant discussed deviations from contracts or regulations with 
government officials and were led to believe that the government accepted the 
changes.  Evidence from government files might also be relevant to the court’s 
interpretation of an arguably ambiguous regulation, an increasingly common issue in 
FCA cases that can implicate both the scienter and falsity analysis.29  Documents 
and testimony concerning how government officials themselves interpreted the 
regulation might admit the regulation is ambiguous or support the defendant’s 
interpretation as correct or at least objectively reasonable.30  Many courts have 
                                                          
request to stay discovery directed against government entities, commenting:  “Why can’t they 
get what you guys [the government] know and did?”). 
 
25
 See Michael J. Davidson, The Government Knowledge Defense to the Civil False 
Claims Act: A Misnomer by Any Other Name Does Not Sound As Sweet, 45 IDAHO L. REV. 41, 
46 (2008); 31 U.S.C. § 3730(b)(4) (LexisNexis 1982) (“unless the Government proceeds with 
the action, the court shall dismiss an action brought by the person on discovering the action is 
based on evidence or information the Government had when the action was brought.”). 
 
26
 See Davidson, supra note 5, at 46-47; Butler v. Hughes Helicopters, Inc., 71 F.3d 321, 
326 (9th Cir. 1995). 
 
27
 Butler, 71 F.3d at 326. 
 
28
 See, e.g., id. at 326-27; United States ex rel. Hagood v. Sonoma Cnty. Water Agency, 
929 F.2d 1416 (9th Cir. 1991); JOHN T. BOESE, CIVIL FALSE CLAIMS AND QUI TAM ACTIONS 
§ 2.06[E] (3d ed. 2010). 
 
29
 See BOESE, supra note 8, at § 2.03[B]. 
 
30
 See United States ex rel. Walker v. R&F Properties of Lake Cnty, Inc., 433 F.3d 1349, 
1356-58 (11th Cir. 2005) (considering Medicare manuals, Medicare bulletins, seminar prog-
rams, and expert testimony to “show the meaning of the language in the regulation and on the 
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recognized—often in dealing with allegedly ambiguous regulations—that the “falsity 
and scienter requirements are inseparable.”31   
Evidence from government entities relating to what it knew and/or allegedly 
“would have done” but for the alleged wrongdoing can be highly relevant issues of 
materiality, causation, damages, and penalties.32  Moreover, courts generally hold 
that if the “government knew what [defendant] was doing and implicitly approved of 
[defendant’s] actions,” the FCA claims fail.33  The strength of that defense, however, 
                                                          
HCFA 1500 form and the reasonableness of [defendant’s] claimed understanding of that lang-
uage,” rejecting district court’s holding that evidence was “irrelevant . . . because none of it 
held the force of law”); Minn. Assoc. of Anesthetists v. Allina Health Sys. Corp., 276 F.3d 
1032, 1053-54 (8th Cir. 2002) (relying on HCFA memorandum, a bulletin published by a 
HCFA fiscal intermediary, and an industry publication to determine whether defendant’s 
interpretation of regulation was objectively reasonable). 
 
31
 United States ex rel. Morton vs. A Plus Benefits, Inc., 139 Fed. Appx. 980, 982 (10th 
Cir. 2005); see also United States ex rel. Wilson v. Kellogg Brown & Root, Inc., 525 F.3d 
370, 377 (4th Cir. 2008) (“‘[I]mprecise statements or differences in interpretation growing out 
of a disputed legal question are similarly not false under the FCA’”) (quoting United States ex 
rel. Lamers v. City of Green Bay, 168 F.3d 1013, 1018 (7th Cir. 1999)); United States v. 
Southland Mgmt. Corp., 326 F.3d 669, 682 n.26 (5th Cir. 2003) (en banc) (Jones, J. 
concurring) (besides scienter, government knowledge “is also bound up with whether the 
claim itself was false”); Massachusetts v. Mylan, 608 F. Supp. 2d 127, 148 (D. Mass. 2008) 
(“Government knowledge could conceivably be relevant to two elements of the FCA: the 
falsity of the claim and the defendant’s state of mind.”); United States v. Prabhu, 442 F. 
Supp.2d 1008, 1032 (D. Nev. 2006) (“Finally, Dr. Prabhu’s claims cannot be false, as a matter 
of law, because under the undisputed facts there is no articulated, objective standards that 
dictates that the documentation underlying the claims is false, inaccurate, or incomplete.”); 
BOESE, supra note 28, at § 2.03[F] (citing cases where courts have indicated government 
knowledge is relevant to issue of falsity). 
 
32
 See Hagood, 929 F.2d at 1421 (“It may be, as the district court observed, that no 
damages were suffered when officers of the United States knowledgeably decided to proceed 
with the contract.”); Cf. United States ex rel. Butler v. Hughes Helicopter Co., 1993 WL 
841192 (C.D. Cal. 1993) (finding, as a matter of law, that there was no “causal connection 
between the allegedly false or incorrect statements made by MDHC and the government’s 
decision to purchase the Apache aircraft” and that, “[c]onsequently, actual damages . . . could 
not have been found as a matter of law”); see United States ex rel. Bunk v. Birkart Globistics 
GmBH & Co., Nos. 1:02cv1168 (AJT/TRJ), 1:07cv1198 (AJT/TRJ) (E.D. Va. Nov. 10, 2010) 
(“[T]he extent of the government’s knowledge and its conduct in light of what it knew 
remains relevant considerations to the Court in considering an appropriate civil penalty.”); 
Neal J. Wilson, The Government Knowledge “Defense” to Civil False Claims Actions, 24 
PUB. CONT. L.J. 43, 60-61 (1994) (“[T]he Government knowledge defense may not be 
successful in precluding False Claims Act liability in every instance, even where the facts 
permit.  The defense, however, should nonetheless be recognized as an effective means of 
precluding, or greatly reducing, the measure of actual damages under the Act, perhaps the 
paramount concern of targeted individuals or contractors.” (collecting cases)).  
 
33
 Englund v. Los Angeles County, 2006 WL 3097941, at *12 (E.D. Cal. 2006);  see also 
Southland Mgmt. Corp., 326 F.3d at 682 n.8 (Jones, J. concurring) (“[t]he governments 
knowledge and acquiescence in its contractor’s actions” is ‘highly relevant’ to determining 
FCA liability”); Mylan Labs., 608 F. Supp.2d 127, 152 (D. Mass. 2008) (“a government 
knowledge defense is viable because the government decided to continue using WACs as a 
policy matter”); United States ex rel. Gudur v. Deloitte, 512 F. Supp.2d 920, 932 (S.D. Tex. 
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“rests upon the depth of the government’s knowledge of the facts underlying the 
allegedly false claims and the degree to which the government invites the claim.”34  
A valid inquiry into the depth of the government’s knowledge, acquiescence, or 
decision-making, of course, requires a reasonably complete factual record from the 
files of relevant governmental entities. 
The subject matter underlying the allegations of three recent areas of FCA 
activity—pharmaceutical pricing, the “off-label” marketing of pharmaceuticals, and 
disputes over Medicaid program funding—demonstrates the increased relevance of 
evidence from government entities in today’s expanding FCA environment.  
A.  Average Wholesale Price Litigation 
The “average wholesale price,” or “AWP,” benchmark reportedly was created in 
the late 1960’s by two pharmacists working for the state of California as a way to 
more efficiently process pharmacy claims submitted to the state’s Medicaid 
program.35  While a novel concept, a list of AWPs did not actually exist at the time.36  
Shortly thereafter, a publication called the Drug Topics Red Book filled the void by 
being the first to publish AWPs; the publication stated the AWP prices had been 
“independently obtained and calculated by Red Book’s editorial staff from a 
representative group of wholesalers located throughout the country.”37  Despite the 
“average wholesale price” moniker, over the next two decades those within the 
pharmaceutical industry—including government officials—came to understand that 
AWPs represented “list prices” which did not account for discounts that most 
pharmacists and physicians negotiated with drug manufacturers and wholesalers.38  
Intense price competition in the generic drug industry led to increasingly large 
discounts, widening the “spread” between reported AWPs and actual sales prices 
                                                          
2007) (“no violation exists where relevant government officials are informed of the alleged 
falsity, thus precluding a determination that the government has been deceived”).  
 
34
 United States ex rel. Burlbaw v. Orenduff, 548 F.3d 931, 952 (10th Cir. 2008) (also 
holding that “neither the directness of the government-contractor communications nor their 
nexus to an existing contractual relationship constitute an essential predicate for the govern-
ment knowledge inference”); Wilson, supra note 32, at 57 (“Successful application of the 
defense where Government assent is unexpressed obviously turns in large part on the quantum 
and quality of evidence demonstrating presubmittal consent.”) 
 
35
 Michael L. Koon, AWP Through the Looking Glass: Industry Litigation by Definition, 




 See id. 
 
37
 See id. 
 
38
 See generally Krause, supra note 19, at 266; OFFICE OF INSPECTOR GENERAL, DEP’T OF 
HEALTH & HUMAN SERV., A-06-40216, CHANGES TO THE MEDICAID PRESCRIPTION DRUG 
PROGRAM COULD SAVE MILLIONS, (Sept. 1984) (“Within the pharmaceutical industry, AWP 
means non-discounted list price. Pharmacies purchase drugs at prices that are discounted 
significantly below AWP or list price. . . . The use of AWP in determining Medicaid 
reimbursement for drugs has been a problem that HCFA has recognized for some time.  
However, efforts to date to control the problem have not been successful.”) 
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paid by pharmacists and physicians.39  Those in the industry joked that “AWP” 
meant “Ain’t What’s Paid.”40 
Nonetheless, third-party payors, including the Medicare and Medicaid programs, 
continued to base their payments to pharmacies and physicians who provided drugs 
to patients  upon the AWPs reported in the Red Book and other pricing 
“compendia”—but usually with only a small discount, typically 5-10%, off the 
AWP.41  The applied discount usually did not reduce Medicare or Medicaid 
payments to the costs paid by pharmacists and physicians to acquire the drugs.42  
Providers were allowed to pocket the difference, which they argued was appropriate 
given untimely and inadequate reimbursement provided for related services.43  
Although this state of affairs was generally well known, efforts at the state and 
federal level to more closely align payments with provider acquisition costs were 
repeatedly rejected—often with little to no explanation.44  The situation developed 
                                                          
 
39
 OFFICE OF THE INSPECTOR GENERAL, DEP’T OF HEALTH & HUMAN SERV., A-06-97-
00011, MEDICAID PHARMACY—ACTUAL ACQUISITION COST OF GENERIC PRESCRIPTION DRUG 




 E.M. Kolassa, Guidance for Clinicians in Discerning and Comparing the Price of 
Pharmaceutical Agents, J. OF PAIN & SYMPTOM MGMT., May 1994, at 235-43; Bill Alpert, 
Hooked on Drugs, BARRON’S, June 10, 1996. 
 
41
 OFFICE OF THE INSPECTOR GENERAL, supra note 39. (finding most common discount 
used by state Medicaid programs was 10% off of AWP).  
 
42
 Id. (calculating savings on generic drugs that could be achieved by state Medicaid 
programs if they reimbursed at a higher 42.5% discount off of AWP instead of the commonly 
used 10% discount). 
 
43
 See, e.g., OFFICE OF INSPECTOR GENERAL, DEP’T OF HEALTH & HUMAN SERV., A-06-95-
00068, REVIEW OF PHARMACY ACQUISITION COSTS FOR DRUGS REIMBURSED UNDER THE 
MEDICAID PRESCRIPTION DRUG PROGRAM OF THE MONTANA DEPARTMENT OF PUBLIC HEALTH 
AND HUMAN SERVICES at App. 4, (July 1996) (Montana Medicaid agency:  “In Montana we 
currently believe that the dispensing fee is below the cost to dispense because of the cap on 
dispensing fees that is currently in place and has been for many years.”); OFFICE OF INSPECTOR 
GENERAL, DEP’T OF HEALTH & HUMAN SERV., A-06-95-00072, REVIEW OF PHARMACY 
ACQUISITION COSTS FOR DRUGS REIMBURSED UNDER THE MEDICAID PRESCRIPTION DRUG 
PROGRAM OF THE VIRGINIA DEPARTMENT OF MEDICAL ASSISTANCE SERVICES at App. 4, (Nov. 
1996) (Virginia Medicaid agency:  “the acquisition cost is just one factor involved in 
pharmacy reimbursement policy or methodology”). 
 
44
 Krause, supra note 19, at 266; OFFICE OF INSPECTOR GENERAL, DEP’T OF HEALTH & 
HUMAN SERV., A-06-00-00023, MEDICAID PHARMACY—ACTUAL ACQUISITION COST OF BRAND 
NAME PRESCRIPTION DRUG PRODUCTS at 1-4, (Aug. 2001) (estimating savings of over $1 
billion that could be achieved on the 200 brand drugs with the highest Medicaid expenditures 
if states modified their AWP discount levels); OFFICE OF INSPECTOR GENERAL, DEP’T OF 
HEALTH & HUMAN SERV., A-06-01-00053, MEDICAID PHARMACY—ACTUAL ACQUISITION 
COST OF GENERIC PRESCRIPTION DRUG PRODUCTS 5, (March 2002) (estimating savings of $470 
million that could be achieved on the 200 generic drugs with the highest Medicaid 
expenditures if states modified their AWP discount levels). Congress finally changed the 
reimbursement system for most Medicare drugs in the Medicare Modernization Act of 2003, 
moving to an “average sales price” system.  See CONG. RESEARCH SERV., RL31199, 
MEDICARE:  PAYMENTS TO PHYSICIANS 24 (Jan. 2008). At the same time, however, Congress 
increased the payments to physicians for administering drugs.   
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into a major policy issue, with President Clinton even commenting on it in a 
December 1997 radio address.45   
Intrigued by this flaw in reimbursement policy—something President Clinton 
referred to as “waste and abuses [that] aren’t even illegal”—relators and state and 
federal prosecutors saw opportunity.  Prosecutors saw a mechanism to fix an 
imperfect reimbursement system.  Relators and plaintiffs’ counsel saw the potential 
for huge awards on millions of allegedly “false” claims, as each drug reimbursement 
claim could be considered a false claim.  Plaintiffs set their litigation sights not on 
the providers who pocketed the drug margin, but instead on upon pharmaceutical 
manufacturers.  While the manufacturers did not typically set the AWP—and there 
was no statute or regulation defining or establishing duties upon manufacturers in 
connection with AWP—plaintiffs argued that manufacturers nonetheless controlled 
the setting of AWP and therefore “caused” the submission of “false” claims by 
pharmacists and physicians.46  In addition to statutory penalties, plaintiffs sought the 
“spread” paid to providers—alleged “overpayments”—as damages from 
manufacturers.  Over the last decade, numerous AWP-related lawsuits were filed, 
resulting in substantial recoveries.47  Many suits are still ongoing. 
                                                          
 
45
 President Clinton remarked:   
Sometimes the waste and abuses aren’t even illegal; they’re just embedded in the 
practices of the system.  Last week, the Department of Health and Human Services 
confirmed that our Medicare program has been systematically overpaying doctors and 
clinics for prescription drugs, overpayments that cost taxpayers hundreds of millions 
of dollars.  Such waste is simply unacceptable. Now, these overpayments occur 
because Medicare reimburses doctors according to the published average wholesale 
price, the so-called sticker price, for drugs.  Few doctors, however, actually pay the 
full sticker price.  In fact, some pay just one tenth of the published price. 
President William Jefferson Clinton, The President’s Radio Address at the White House 
(Dec.13, 1997), in 33 WEEKLY COMPILATION OF PRESIDENTIAL DOCUMENTS 2033, 2033-34 
(Dec. 22, 1997), available at http://www.gpo.gov/fdsys/pkg/WCPD-1997-12-22/html/WCPD-
1997-12-22-Pg2033-2.htm.   
 
46
 U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-01-1142T, MEDICARE PART B DRUGS: 
PROGRAM PAYMENTS SHOULD REFLECT MARKET PRICES (Sept. 21, 2001) (“The term AWP is 
not defined in law or regulation, so the manufacturer is free to set AWP at any level, 
regardless of the actual price paid by purchasers.”). 
 
47
 The federal government first intervened in AWP-related litigation in 2001, when Bayer 
and TAP Pharmaceuticals settled criminal and civil claims that included allegations relating to 
AWP manipulation. Koon, supra note 35. Over the next decade, the federal government has 
settled several other qui tam cases relating to AWP.  See, e.g., Press Release, U.S. Dep’t of 
Justice, Bayer To Pay $14 Million To Settle Claims For Causing Providers To Submit Fraud-
ulent Claims To 45 State Medicaid Programs (Jan. 23, 2001), available at http://www.justice 
.gov/opa/pr/2001/January/039civ.htm; Press Release, U.S. Dep’t of Justice, TAP Pharmace-
utical Products Inc. and Seven Others Charged With Health Care Crimes; Company Agrees 
To Pay $875 Million To Settle Charges (Oct. 2, 2001), available at http://www.justice.gov/op 
a/pr/2001/October/513civ.htm; Press Release, U.S. Dep’t of Justice, AstraZeneca Pharmac-
euticals LP Pleads Guilty To Healthcare Crime; Company Agrees To Pay $355 Million To 
Settle Charge (June 20, 2003), available at http://www.justice.gov/opa/pr/2003/June/03_civ 
_371.htm; Press Release, U.S. Dep’t of Justice, Bristol-Myers Squibb to Pay More Than $515 
Million to Resolve Allegations of Illegal Drug Marketing and Pricing (Sept. 28, 2007), 
available at http://www.justice.gov/opa/pr/2007/September/07_civ_782. html; Press Release, 
U.S. Dep’t of Justice, Pharmaceutical Manufacturers to Pay $421.2 Million to Settle False 
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Pharmaceutical manufacturers have defended plaintiffs’ claims on numerous 
grounds, many that relied principally on evidence—to the extent it still exists—from 
state and federal government entities.48  Indeed, in the closing argument of one state 
AWP case, defense counsel noted that “[m]ost of . . . our defense is built on 
witnesses from the state.”49  Manufacturers have pointed to widespread knowledge 
of spreads and concomitant inaction by government entities as evidence that 
government programs acquiesced in the payment of spreads for a variety of reasons, 
including the need to subsidize inadequate dispensing fees, encourage the use of 
certain drugs, or  ensure access to care from pharmacy and physician providers who 
threatened to leave government programs if reimbursements were reduced.50  One 
                                                          
Claims Act Cases (Dec. 7, 2010), available at http://www.justice.gov/opa/pr/2010/December/ 
10-civ-1398.html (Roxane Laboratories, Inc., Abbott Laboratories, Inc., and B. Braun Medical 
Inc.); Press Release, U.S. Dep’t of Justice, Pharmaceutical Manufacturer to Pay $280 Million 
to Settle False Claims Act Case (Dec. 20, 2010), available at http://www.justice.gov/opa/pr/ 
2010/ December/10-civ-1464.html (Dey Inc., Dey Pharm L.P. and Dey L.P. Inc.). Numerous 
states have also instituted and received significant recoveries in AWP-related actions. See, 
e.g., Press Release, $89 Million Settlement Reached in Alabama Medicaid Fraud Case (May 
22, 2009), available at http://www.beasleyallen.com/news/$89-million-settlement-reached-in-
Alabama-Medicaid-fraud-case; Press Release, California Office of Attorney General, Brown 
Settles $21.3 Million Medi-Cal Fraud Suit with Pharmaceutical Giant Schering-Plough (Dec. 
17, 2009), available at  http://www.contractormisconduct.org/ass/contractors/178/cases/1261/ 
1792/schering-plough-albuterol_calpr.pdf; Press Release, Jack Conway, Office of the Kentu-
cky Attorney General, Attorney General Conway Announces $10 Million Settlement With 
Drug Company (Aug. 13, 2010), available at http://migration.kentucky.gov/Newsroom/ag/ 
tevaawpsettlement.htm; Press Release, Hawaii Department of the Attorney General, Hawai’i 




 Courts have almost uniformly rejected government attempts to limit discovery from 
governmental entities in AWP mattes.  See, e.g., Agreed Orders on Mot. in Limine, 
Commonwealth of Kentucky ex rel. Jack Conway, Attorney General v. Alpharma NSPD, Inc., 
No. 04-cr-1487, slip op. (June 24, 2009) (on file with author) (denying Kentucky’s motion to 
exclude “government knowledge evidence” and permitting defendants to introduce “evidence 
of cross-subsidization” and “evidence that pharmacy participation in the Medicaid program 
was a concern”); Decision and Order on Plaintiffs Motion Partial Summary Judgment Against 
Defendants Novartis, AstraZeneca, Sandoz, and Johnson & Johnson, State of Wisconsin v. 
Abbott Laboratories, No. 04 CV 1708, slip op at 6 (Wis. Cir. Ct. May 20, 2008) (on file with 
author) (“Plaintiff’s argument that ‘[a]n untrue statement is untrue regardless of whether the 
listener knows it is untrue’ . . . begs the question.  How is a statement ‘untrue’ in the first 
place, if the speaker and listener are using terms they mutually understand because they have 
agreed on their meaning- that is, they have together developed the definitions, either expressly 
or tacitly, such that they have a common understanding?”). 
 
49
 Trial Tr. at 3909, Commonwealth of Pa. v. Bristol Myers Squibb Co., No. 212 MD 2004 
(Pa. Commw. Ct. Sept. 7, 2010) (on file with author). 
50
 See generally Defendants Combined L.R. 56.1 Stmt. of Additional Material Facts Pertinent 
to the U.S.’s Motion for Partial Summary Judgment Against Defendants., No. 6447, In re 
Pharm. Indus. Average Wholesale Price Litig., MDL 1456, No. 01-CV-12257-PBS (D. Mass. 
Aug. 28, 2009). 
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commentator has observed that the use of AWP was a “loophole” that the 
government did “not yet [have] the political will to close.”51   
These contentions raise disputed factual questions potentially relevant to issues 
of acquiescence, falsity, causation, materiality, and scienter for which evidence from 
government entities would be critical.  Evidence from government entities and their 
contractors has also been vitally important to questions of damages, including as to 
whether, and the extent to which, reported AWPs actually impacted the 
government’s payment amount (for example, when Medicare based its payment on a 
“median” of AWPs across many manufacturers’ products).  
B.  Off-Label Marketing of Pharmaceuticals Litigation 
Another notable area where relators and government prosecutors have 
aggressively used the FCA concerns the “off-label” marketing of prescription drugs.  
“Off-label” refers to any use of a drug that has not been approved by the FDA.52  
Off-label use is both common and legal, the theory being that the physician is in the 
best position to evaluate the risks and benefits of using the drug to treat a particular 
condition.53  But off-label use can be controversial.  Some criticize the practice as 
lacking in scientific evidentiary support, avoiding the clinical testing necessary for 
FDA approval, and posing unnecessary safety risks.54 
While off-label use is legal, drug manufacturers are restricted by Food and Drug 
Administration regulations promoting drugs for off-label use.  Starting with the 
groundbreaking case of United States ex rel. Franklin v. Parke-Davis,55 which 
involved the drug Neurontin, relators sought to connect manufacturers’ alleged 
violations of the FDA’s regulations with the submission by pharmacists and 
                                                          
 
51
 See Krause, supra note 19, at 273; Marc J. Scheineson, Lessons From Expanded 
Government Enforcement Efforts Against Drug Companies, 60 FOOD & DRUG L. J. 1, 7 (2005) 
(observing that the government’s increased efforts to use fraud statutes “to force settlements 
by drug and device manufacturers for conduct that was, in large part, viewed by FDA and 
other agencies as acceptable industry practice until DOJ and OIG began to redefine the 
regulatory landscape”).  Id. 
 
52
 See Joshua Cohen, Andrew Wilson & Laura Faden, Off-Label Use Reimbursement, 64 
FOOD AND DRUG L. J. 391, 392 (2009) (discussing how off-label uses commonly originate). 
 
53
 See Washington Legal Found. v. Henney, 202 F.3d 331, 333 (D.C. Cir. 2000) (“the 
prescription of drugs for unapproved uses is commonplace in modern medical practice and 
ubiquitous in certain specialties”); Gregory Conko & Henry I. Miller, Off Target On Off-Label 
Drugs, FORBES, May 12, 2010 (stating some estimates indicate that off-label uses account for 
at least 20% of all prescriptions and as many as half of all prescriptions for cancer and cardiac 
care); Cohen, et al., supra note 52, at 392 (citing report by the National Comprehensive 
Cancer Network finding 50-75% of all uses of anti-cancer therapy are off-label); Veronica 
Henry, Off-Label Prescribing:  Legal Implications, 20 J. LEGAL MED. 365, 365 (1999) 
(indicating that the American Medical Association reported in 1995 that approximately one-
half of all prescriptions were written for off-label uses). 
 
54
 Robert Kaufman, The Neurontin Controversy:  The Saga of Off-Label Drug Regulation 
Continues (April 27, 2004), available at http://leda.law.harvard.edu/leda/data/638/Kaufman 
.html; Lansdale, supra note 8, at 168; Cohen, et al., supra note 52, at 393.    
 
55
 United States ex rel. Franklin v. Parke-Davis, 147 F. Supp.2d 39, 45 (D. Mass. 2001).  
According to the court’s opinion in Park-Davis, approximately 50% of Neurontin’s sales in 
1996 were attributable to off-label uses.  See id. 
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physicians of “false” claims to Medicare and Medicaid programs for off-label drug 
use.   Arguing a theory of FCA liability that the court in Parke-Davis noted “t[ook] 
the parties into territory that is not well charted by the existing decisional law,”56 the 
relator claimed that Parke-Davis “engaged in an extensive and far-reaching 
campaign to use false statements to promote increased prescriptions of Neurontin . . . 
for off-label uses which caused the filing of false claims for reimbursement by the 
federal government.”57  The relator’s theory of liability, however, hinged largely on 
the debatable premise that Medicaid did not legally permit—or at least knowingly 
allow—reimbursement for certain off-label uses not recognized as a “medically 
accepted indication.”58  The case eventually settled for $430 million, $190 million of 
which was paid to resolve FCA claims.59  The Neurontin case would be only the 
beginning of a wave of high-stakes FCA off-label litigation that continues today, 
many that have resulted in enormous settlements.60   
                                                          
 
56
 Id. at 53. 
 
57
 Id. at 45. 
 
58
 Id. at 44-45.  Federal law requires states to pay for “covered outpatient” drugs used for a 
“medically accepted indication,” meaning the use is specifically approved by the FDA or 
“supported” by specified drug compendia.  42 U.S.C. § 1395r-8(k)(6), (g)(1)(B)(i).  In a 
subsequent decision, the court in the Neurontin litigation acknowledged an open question as to 
whether most states are permitted under federal law to reimburse off-label uses that are not 
“supported” by the compendia.  See United States ex rel. Franklin v. Parke-Davis, Civ. A. No. 
96-11651-PBS, 2003 U.S. Dist. LEXIS 15754, at *7-9 (D. Mass. Aug. 22, 2003).  The court 
did signal, however, that it favored the defendant’s position that federal law did not prohibit 
reimbursement.  See id.  Subsequently, CMS appears to have rejected the relator’s argument in 
the Neurontin litigation that federal Medicaid law prohibits reimbursement of off-label 
prescriptions not “supported” by the compendia.  See Dec. 6, 2007 Letter from CMS to State 
of Utah (on file with author), available at http://psychrights.org/education/ModelQuiTam/071 
206CMSRepl2 DStallard.pdf. (“Section 1927(d) of the Act authorizes States to exclude or 
otherwise restrict coverage of a covered outpatient drug if the prescribed use is not for a 
medically accepted indication (as defined in section 1927(k)(6) of the Act), however, it does 
not explicitly require them to do so.  States are responsible for defining this coverage in their 
app-roved Medicaid State plan and implementing policies.”).  See id.  More recently, relators 
and government prosecutors have argued that alleged “kickbacks” paid by manufacturers to 
physicians render off-label claims for reimbursement “false,” an argument that was recently 
rejected—at least for pending claims—by a court. See United States ex rel. Rost v. Pfizer, 
Inc., Civ. Action No. 03-11084-PBS, 2010 WL 3554719, at *8-10 (D. Mass. Sept. 14, 2010). 
 
59
 Press Release, U.S. Dep’t of Justice, Warner-Lambert To Pay $430 Million To Resolve 
Criminal & Civil Health Care Liability Relating To Off-Label Promotion (May 13, 2004), 
available at http://www.justice.gov/ opa/pr/2004/May/04_civ_322.htm.  
 
60
 See, e.g., Press Release, U.S. Dep’t of Justice, Pharmaceutical Company Cephalon to 
Pay $425 Million for Off-Label Drug Marketing (Sept. 29, 2008), available at http://www.jus 
tice.gov/opa/pr/2008/September/08-civ-860.html; Press Release, U.S. Dep’t of Justice, Eli 
Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promo-
tion of Zyprexa (Jan. 15, 2009), available at http://www.justice.gov/civil/ocl/cases/Cases/El 
i_Lilly/Lilly%20Press%20Release%20Final%2009-civ-038.pdf; Taxpayers Against Fraud 
Education Fund, Top 100 FCA Cases, TAF.ORG, available at http://www.taf.org/general -
resources/top-100-fca-cases (last visited April 6, 2013); Press Release, U.S. Dep’t of Justice, 
Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-label Drug Marketing (April 
27,  2010), available at http://www.justice.gov/opa/pr/2010/April/10-civ-487.html; Press 
Release, U.S. Dep’t of Justice, Novartis Vaccines & Diagnostics to Pay More Than $72 
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Evidence from governmental entities can also play an important role in the off-
label marketing cases.  Each state’s contemporaneous knowledge and policies 
regarding reimbursement for off-label use—which may depend on the specific drugs 
at issue—could be determinative to whether claims for off-label prescriptions are 
considered “false.”61  Moreover, as noted in a recent article, “state Medicaid 
databases will yield large amounts of information about how and why the drug was 
prescribed” and “the state may have access to medical records which may yield 
evidence about the number of actual off-label prescriptions.”62  The article also notes 
that “depositions of state-employed pharmacists or physician may further undercut 
the state’s claim that the drug is dangerous or ineffective,” particularly since state 
attorneys general typically do not consult with public health officials prior to filing 
suit.63  Discovery from the state might also show that the state previously rejected 
proposals to restrict off-label use, which would appear inconsistent with the 
plaintiffs’ FCA claims.  Indeed, even after numerous lawsuits have alleged that 
Medicaid programs are not permitted to reimburse off-label uses not listed in the 
compendia, it appears that most Medicaid agencies continue to do so.64 
                                                          
Million to Resolve False Claims Act Allegations Concerning TOBI (May 4, 2010), available 
at http://sanfrancisco.fbi.gov/dojpressrel/ pressrel10/sf050410.htm; Press Release, U.S. Dep’t 
of Justice, Two Johnson & Johnson Subsidiaries to Pay Over $81 Million to Resolve Allega-
tions of Off-Label Promotion of Topamax (Apr. 29, 2010), available at http://www.justice.go 
v/opa/pr/2010/April/10-civ-500.html; New Whistleblower Law on Medicaid Fraud Signed 
Today by Governor of Georgia, WHISTLEBLOWER LAWYER BLOG (May 24, 2007), available at 
http://www.whistleblowerlawyerblog.com/2007/05/new_ whistleblower_law_on_medic_1.h 
tml (“Many states have taken action against pharmaceutical companies over ‘off-label’ mark-
eting of drugs.”).  
 
61
 A 2009 report published by the Food and Drug Law Journal entitled “Off-Label Use 
Reimbursement” highlights the importance of such evidence.  See Cohen, et al., supra note 
52. Updating a study published 14 years earlier, the authors surveyed 179 third-party payors 
administering Medicare and Medicaid pharmacy benefits to examine both their coverage, and 
criteria for covering, of off-label prescriptions. Id. at 397.  20 state Medicaid agencies 
responded to the survey. Id. The study found that “most [public] payors reimburse off-label 
uses,” and that “payors vary considerably both in their policies regarding payment off-label 
uses, as well as the sources used to justify their reimbursement decisions.”  Id.  
 
62
 See Brian C. Anderson & Michael E. Stamp, Shooting the Messenger: ‘Off-Label 
Marketing’ Attacks Against Pharmaceutical Companies by State Attorneys General, AM. 
ENTER. INST., available at http://www.aei.org/files/2008/05/21/20080522_Andersonpaper.pdf 
(last visited June 10, 2013). 
 
63
 Id. at 13-14. 
 
64
 See Cohen, et al., supra note 52, at 400; Anderson & Stamp, supra note 62, at 12 (citing 
Julie Schmit, Drugmaker Admitted Fraud, but Sales Still Flourish, USA TODAY, Aug. 16, 
2004, at 1A (“Indeed, four years after the case was settled, only 4 of 50 state Medicaid 
programs now require pre-approval of Neurontin prescriptions to ensure that it is being used 
for FDA-approved purposes. . . . It cannot be doubted that states are aware that they are 
paying for off-label use of Neurontin.  Nor can it be doubted that states have it within their 
power to avoid payment for off-label use of Neurontin if they really believe it improper, but 
they refrain from doing so.”). 
2013] THE DARK SIDE OF THE BOOM 197 
 
C.  Federal Funding Challenges 
A final example relates to the politically sensitive topic of how the federal 
government funds Medicaid.  Because the federal government pays at least a 
majority of Medicaid expenditures, Medicaid can be seen as a mechanism of getting 
federal dollars into the states.65  Relators and government prosecutors have recently 
turned to the FCA in an attempt to curb allegedly abusive schemes in this area.  For 
example, in United States ex rel. Englund v. Los Angeles County, the relator sued the 
County of Los Angeles for allegedly conspiring with the state of California to 
receive unwarranted Medicaid matching funds.66  The relator claimed that federal 
Medicaid matching dollars—paid through so-called “intergovernmental transfers” 
(IGTs) between the state and local governments—were paid to healthcare providers 
(including the County) at amounts which exceeded the providers’ cost of providing 
services.67  The surplus was deposited into the County’s general funds and was 
allegedly “expended for non-Medicaid, and even non-healthcare purposes.”68  The 
                                                          
 
65
 See Robert B. Helms, Medicaid: The Forgotten Issue in Health Reform, HEALTH POLICY 
OUTLOOK (Am. Enter. Inst. for Pub. Policy Research, Washington, D.C.) (Nov. 6, 2009), 
available at http://www.aei.org/article/health/healthcare-reform/medicaid-the-forgotten-issue-
in-health-reform/ (“Since no one state ever pays the full cost of its Medicaid program, each 
state has an incentive to expand its program when the economy is expanding and state 
revenues are increasing.”); Robert B. Helms, The Medicaid Commission Report: A Dissent, 
(Jan. 12, 2007), available at http://www.aei.org/article/society-and-culture/poverty/the-
medicaid-commission-report/(describing incentives for states to increase Medicaid spending 
by virtue of the federal match and a “tug of war” between state and federal governments to 
control schemes to enhance federal matching); James Frogue, Medicaid’s Perverse Incentives, 
STATE FACTOR (July2004) (“The federal match that states receive is open-ended.  No matter 
how much a state spends on Medicaid, the federal government will add on the pre-determined 
match rate. This creates strong incentives for states to not only spend more on Medicaid, but 




 Englund v. Los Angeles Cnty, 2006 WL 3097941, at *1 (E.D. Cal. 2006). 
 
67
 Id. at *2-4. 
 
68
 Id. at *4, 8-9.  The court described the essential facts as follows: 
Under SB 1255 certain providers of Medicaid services can seek supplemental 
Medicaid funding.  The County is one such provider.  Under SB 1255, IGTs from 
public entities (such as the County) are used for the non-federal share of the 
supplemental funds.  In other words, at the time at issue in this case, the County would 
transfer money to the State, which in turn, would use that money to apply for 
matching funds from the Federal government. Providers such as the County could 
seek up to 175% of uncompensated costs under SB 1255.  The idea was that the State 
would “put up” part of the funds and then the Federal government would “match” the 
State's contribution. 
Once the State made the SB 1255 payment to the County (which consisted of both the 
State and Federal shares), the “net” amount would go to the hospitals (the gross 
payment minus the IGT amount) and the amount of the initial IGT would go to the 
County’s general DHS fund. 
Id. at *8. 
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court noted IGTs were a “controversial” mechanism to “‘pull down’ federal money’” 
that was “not necessarily popular with Congress and CMS.”69   
A recent case in which the government intervened, United States ex rel. Baker v. 
Community Health Systems, Inc., presents similar issues. 70  There, plaintiffs contend 
that New Mexico hospitals made legal, but “non-bona fide” donations to various 
New Mexico counties that resulted in the state of New Mexico submitting false 
claims for federal matching dollars to the federal government.71  Plaintiffs alleged 
that the “64 Forms” submitted by the state for federal reimbursement dollars were 
false because they failed to deduct the allegedly “non-bona fide” donations, further 
contending that defendants “devised a fraudulent scheme” to “receiv[e] back 
Medicaid payments in the amount of their payments plus triple those amounts from 
the resulting federal financial participation.”72 For their part, defendants claim the 
suit is a “funding dispute” between the State of New Mexico and the federal 
government, and that CMS and state officials were “fully informed of and approved 
the claims at issue in accordance with applicable statutes and regulations.”73  
In both Englund and Community Health Systems, evidence from government 
entities is important and, at least in the Englund case, dispositive.  In Englund, the 
court granted Defendant’s motion for summary judgment based upon “extensive 
evidence that officials on both the State and Federal levels were well aware of the 
County’s actions and understood the alleged ‘scheme’ to be legal.”74  For example, 
the Court cited testimony from CMS Administrator Thomas Scully, who testified 
that “almost every state was doing that [transferring money to the general fund] to 
some degree,” that he “was very aware of what they were doing all along,” and that 
“everybody in Congress understood it was a total scam, but it happened to be a scam 
Congress authorized.”75  Similarly, in the Community Health Systems litigation, the 
defendants’ pleadings suggest that their defense will rely heavily on the fact that 
state and federal officials were fully aware of and approved the alleged payments 
that plaintiffs now label “false.”76  In fact, as discussed more fully below, the 
                                                          
 
69
 Id. at *2, 16. 
 
70
 United States ex rel. Baker v. Cmty. Health Sys., Inc., Civil No. 05-279 WJ/WDS, Slip 
op. at 6-8, 13-14, 18 (D.N.M. July 7, 2010).  
 
71
 Id.  
 
72
 Id. at 6; see generally id. at 7, 13-14, 18.  
 
73
 United States ex rel. Baker v. Cmty. Health Sys., Inc., Civil No. 05-279 WJ/WDS (D. 
N.M. Aug. 28, 2009) (Memorandum of Law in Support of Defendants Motion to Dismiss the 
Complaint of the United States in Intervention) available at 2009 WL 2823668; Answer and 
Affirmative Defense of Defendant Community Health Systems, Inc. at ¶¶ 411-13, United 
States ex rel. Baker v. Cmty. Health Sys., Inc., Civil No. 05-279 WJ/WDS (D. N.M. July 21, 
2010).   
 
74
 U.S. ex rel. Englund v. Los Angeles Cnty., No. CIV S.-04282 LKK/JFM, 2006 WL 
3097941, at *12-16 (E.D. Ca. Oct. 31, 2006). 
 
75
 Id. at *13-14.  The court also cited Congressional testimony from CMS’s top Medicaid 
official, who admitted that he was aware of the practice and believed it was “inappropriate, 
but . . . not illegal.”  Id. at *15. 
 
76
 Answer and Affirmative Defense of Defendant Community Health Systems, Inc. at 
¶¶ 411-17, United States ex rel. Baker v. Cmty. Health Sys., Inc., Civil No. 05-279 WJ/WDS 
(D. N.M. July 21, 2010). 
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defendants in this case successfully filed a motion for sanctions against the 
government for failing to preserve its files.77  
AWP, off-label marketing, and federal funding disputes are only a few examples 
of the increasingly broad and creative ways that relators and government prosecutors 
have used the FCA to challenge perceived flaws or “loopholes” in government 
reimbursement policy.  Other examples FCA claims relate to Medicare “outlier” 
payments, suits alleging deceptive practices by pharmacy benefit managers (PBMs) 
concerning drug “switching” and the retention of Medicaid drug rebates, and cases 
alleging that healthcare equipment manufacturers overcharged government 
programs.78  These actions have also led to substantial settlements.79  These cases, 
too,  involve allegations where evidence from governmental entities can be critical.80   
                                                          
 
77
 See United States ex rel. Baker v. Cmty. Health Sys., Inc., Civil No. 05-279 WJ/ACT, 
2012 U.S. Dist. LEXIS 146865 (D. N.M. Aug. 31, 2012). 
 
78
 For a discussion of the Medicare outlier allegations, see Elizabeth A. Weeks, Loop-
holes: Opportunity, Responsibility, or Liability, 35 J.L. MED. & ETHICS 320, 322-23 (Summer 
2007); R. Brent Rawlings & Hugh E. Aaron, The Effect of Hospital Charges On Outlier 
Payments Under Medicare's Inpatient Prospective Payment System: Prudent Financial 
Management or Illegal Conduct?, 14 ANN. HEALTH L. 267 (Summer 2005); see DAVID A. 
BALTO, PROACTIVE LITIGATION AGAINST PBMS (2006), available at http://www.ncpanet.o 
rg/pdf/legal_summary_suits_vs_pbms.pdf (discussing state and federal false claims act claims 
relating to PBMs); see What Health Reform Won’t Cure, ZIMBIO.COM (Dec. 18, 2009), http:// 
www.zimbio.com/BusinessWeek/ articles/tyQqH6BDB7T/WHAT+HEALTH+REFORM+W 
ON+T+CURE (discussing FCA suit against Siemens for allegedly overcharging the 
Department of Veterans Affairs for medical equipment). 
 
79
 See, e.g., Press Release, U.S. Dep’t of Justice, Tenet Healthcare Corporation To Pay 
U.S. More Than $900 Million To Resolve False Claims Act Allegations (June 29, 2006), 
available at http://www.justice.gov/opa/pr/2006/June/06_civ_406.html; Press Release, U.S. 
Dep’t of Justice, Largest Health Care System In New Jersey To Pay U.S. $265 Million To 
Resolve Allegations Of Defrauding Medicare (June 15, 2006), available at http://www.justice. 
gov/opa/pr/2006/June/06_civ_373.html; Press Release, U.S. Dep’t of Justice, Houston's 
Methodist Hospital To Pay U.S. More Than $9 Million To Resolve Allegations Of Over-
charging Medicare (Mar. 26, 2009), available at http://www.justice.gov/opa/pr/2009/M 
arch/09-civ-274.html; Press Release, U.S. Dep’t of Justice, New Jersey Hospital to Pay $6.35 
Million to Resolve Allegations of Inflating Charges to Obtain Higher Medicare Reim-
bursement (Mar. 19, 2010), available at http://newark.fbi.gov/dojpressrel/pressrel10/nk 
031910.htm; Press Release, U.S. Dep’t of Justice, Parent Company of Two New Jersey 
Hospitals to Pay U.S. $7.95 Million to Settle False Claims Act Allegations (Dec. 15, 2009), 
available at http://www.justice.gov/opa/pr/2009/December/09-civ-1350.html; Press Release, 
U.S. Dep’t of Justice, Cathedral Healthcare System to Pay U.S. $5.3 Million to Resolve 
Allegations Involving Inflated Charges to Obtain Higher Medicare Reimbursement (Mar. 4, 
2008), available at http://www.justice.gov/opa/pr/2008/March/ 80_civ_167.html; Balto, supra 
note 78 (discussing settlements of FCA cases involving PBMs).  
 
80
 See, e.g., Memorandum of Law in Support of Defendant’s Motion for Summary 
Judgment at 1, 5, States ex rel. Thomas v. Siemens Medical Solutions USA, Inc., Civ. No. 99-
4414-TJS (E.D. Pa. Oct. 22, 2010) (quoting the court’s statement that “the greatest discovery 
you are going to get is what the government tells you,” and arguing that discovery showed 
“the VA accepted varying interpretations of, and disclosures on, the DPI—after extensive 
audits and with full understanding of the very pricing information [relator] contends was 
fraudulently misstated and omitted”). 
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In sum, as FCA allegations and legal theories continue to evolve and expand, 
evidence on what responsible government officials understood, accepted, and 
intended becomes increasingly critical to resolving these disputes fairly and in the 
interests of justice. 
IV.  UNIQUE ISSUES OF SPOLIATION IN FALSE CLAIMS ACT LITIGATION   
The integrity of our judicial system depends on the preservation of relevant 
evidence.  Judge Allegra of the United States Court of Federal Claims put it well:  
“Aside perhaps from perjury, no act serves to threaten the integrity of the judicial 
process more than the spoliation of evidence,” as “when critical documents go 
missing, judges and litigants alike descend into a world of ad hocery and half 
measures—and our civil justice system suffers.”81  While there is no dispute that 
“[i]t is the duty of the United States, no less than any other party . . .  to ensure . . .  
that documents relevant to a case are preserved,”82 FCA cases present special 
challenges.   
A.  An Unregulated Seal Period and Generous Statute of Limitations Can Delay 
False Claims Act Cases Indeterminately. 
A relator-instituted FCA qui tam action must be filed under seal.83  By statute, 
the case remains under seal for at least 60 days, during which time the government is 
supposed to conduct an investigation to decide whether to intervene.84  While 
Congress believed this 60-day period would be adequate in “the vast majority of 
cases,”85 in practice the government may, and usually does, ask the court to extend 
the seal.86  Repeated extension requests—often for six months at a time—are now 
the rule.87   
                                                          
 
81
 United Med. Supply Co. v. United States, 77 Fed. Cl. 257, 258-59 (2007). Magistrate J. 
Schenkier writes:  
Parties and attorneys frequently are called upon to preserve and produce documents 
that are against their interest in a particular case.  And when they do so, the parties and 
the attorneys uphold the integrity of our litigation system and inspire confidence in it.  
Conversely, when a charge is made that relevant information has been destroyed, and 
especially when a charge is made of intentional destruction, it is a charge that strikes 
at the core of our civil litigation system. 




 United Med. Supply, 77 Fed. Cl. at 274. 
 
83






 S. REP. NO. 99-345, at 25 (1986), reprinted in 1986 U.S.C.C.A.N. 5266, 5290. 
 
86
 31 U.S.C. § 3730(b)(3).  
 
87
 See False Claims Act Cases: Government Intervention in Qui Tam (Whistleblower) 
Suits, U.S. DEP’T OF JUSTICE, https://www.doioig.gov/docs/falseclaimsact.pdf (last visited 
April 6, 2013).  
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The FCA’s increased popularity, coupled with government staffing shortfalls and 
other strategic factors, has produced a sizeable backlog of cases sitting under seal.88  
A January 2011 letter from the DOJ to Senator Charles Grassley indicated that there 
were 1,341 FCA qui tam cases under seal still awaiting the DOJ’s decision on 
intervention.89  Some cases, particularly high-stakes cases, have sat under seal for 
several years.90  Congress did not intend this unfortunate backlog.  The legislative 
history to the 1986 FCA amendments states that a “mere[ ] showing that the 
Government was overburdened” would not justify extending the seal, cautioning that 
the “Government should not, in any way, be allowed to unnecessarily delay lifting of 
the seal from the civil complaint or processing of the qui tam litigation.”91 
Courts, and even counsel representing relators, have expressed dismay about 
inordinate delays in FCA cases.  In the AWP litigation, Judge Saris stated: 
These long delays are quite troubling.  Evidence spoils, memories fade, 
and prejudice may result.  In my experience, the government routinely 
files for multiple extensions of time, frequently citing as the reason the 
size of the case and lack of resources to investigate adequately.  At some 
point, though, the government must fish or cut bait.92 
Similarly, another court commented that “the multiple interventions [by the 
government] . . .  [which] appear to the Court to have no other justification than to 
allow the government to investigate and settle the multiple claims at its own pace, 
selectively carving out those claims that were easiest to settle while keeping the 
                                                          
 
88
 See Carrie Johnson, A Backlog of Cases Alleging Fraud, Whistle-Blower Suits Languish 
at Justice, WASH POST (July 2, 2008), http://www.washingtonpost.com/wp-dyn/content/articl 
e/2008/07/01/AR2008070103071.html (“By its own account, the 75-lawyer unit in 
Washington that reviews the sensitive lawsuits is overloaded and understaffed.  Only about 
100 cases a year are investigated by the team, which works out of the commercial litigation 
branch of Justice’s civil division.”). 
 
89
 See Letter from J. Esquea, Asst. Sec. U.S. Dep’t of Health and Human Res. & R. 





 See, e.g., In re Pharm. Indus. Average Wholesale Price Litig., 498 F. Supp.2d 389, 398-
99 n.6 (D. Mass. 2007) (action remained under seal for more than ten years); United States v. 
Baylor Univ. Med. Ctr., 469 F.3d 263, 266 (2d Cir. 2006) (government made sixteen separate 
requests to extend the seal over an eight-year period); United States ex rel. Health Outcomes 
Techs. v. Hallmark Health Sys.,Inc., 409 F. Supp.2d 43, 50 (D. Mass. 2006) (“The govern-
ment’s investigation dragged on incessantly, and with respect to these particular hospital-
defendants seven years, until it chose officially to intervene.”); How the False Claims Act 
Works, WARREN BENSON LAW GROUP, available at http://www.warrenbensonlaw.com/how-it-
works/ (“Your False Claims Act lawsuit will typically remain sealed for up to 2 to 3 years, 




 S. REP. NO. 99-345, at 24-25 (1986), reprinted in 1986 U.S.C.C.A.N. at 5289-5290.  
The legislative history also indicates that, by “providing for sealed complaints, [Congress] did 
not intend to affect defendants’ rights in any way.”  Id. at 8. 
 
92
 In re Pharm. Indus. Average Wholesale Price Litig., 498 F. Supp. 2d at 402 n.6.  
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remaining defendants in limbo until it chose to act against them.”93  Recently, some 
courts have become so frustrated with government foot-dragging that they have 
unsealed the relator’s complaint before the government’s decision on intervention.94   
Normally, statutes of limitations serve to prevent stale claims.  “Such statutes 
‘promote justice by preventing surprises through the revival of claims that have been 
allowed to slumber until evidence has been lost, memories have faded, and witnesses 
have disappeared.’”95  The FCA’s statute of limitations, however, is very generous to 
the government: 
(1) more than 6 years after the date on which the violation of section 3729 
is committed, or  
(2) more than 3 years after the date when facts material to the right of 
action are known or reasonably should have been known by the official of 
the United States charged with responsibility to act in the circumstances, 
but in no event more than 10 years after the date on which the violation is 
committed, whichever occurs last.96 
Thus, even before the operation of the “relation-back” doctrine, a defendant 
could be subject to liability for conduct that occurred ten years ago.97  But under the 
relation-back doctrine, liability might reach back even further, particularly in cases 
with a lengthy DOJ investigation. Prior to the 2009 FERA amendments, courts were 
split on whether a government’s complaint-in-intervention could relate-back to the 
relator’s under seal complaint.98  But FERA now provides that the government’s 
                                                          
 
93
 United States v. St. Joseph’s Reg’l Health Ctr., 240 F. Supp. 2d 882, 888 (W.D. Ark. 
2002).  See also Health Outcomes, 409 F. Supp. 2d at 50 (“The government’s investigation 
dragged on incessantly, and with respect to these particular hospital-defendants seven years, 
until it chose officially to intervene.”); War Profiteering And Other Contractor Crimes 
Committed Overseas:  Hearing Before the Subcomm. on Crime, Terrorism, and Homeland 
Security of the H. Comm. on the Judiciary, 110th Cong. 41 (2007) (statement of Alan 
Grayson, whistleblower attorney) (“To prevent the abuse of this sealing provision, which is 
only supposed to be in effect for 60 days—but, in this case, 60 days becomes 60 weeks and 
almost 60 months—there needs to be a firm limit on extensions of the seal. Clearly, 1 year is 
enough. The seal is meant to help to uncover fraud, not to bury it.”); Johnson, supra note 88 
(noting district court judge hearing FCA case “blasted civil division lawyers for ‘doing 
virtually nothing’ to follow up for four years after [relator] brought forward allegations in 
1995 about bid rigging on construction contracts in Egypt,” which led to ‘loss of evidence, 
fading memories, [and] disappearance of documents’”). 
 
94
 See Sheri Qualters, Cases Deluge Boston Court, Federal Judges Have Begun to Unseal 
Idling False Claims Act Suits, NAT’L L. J. (Aug. 1, 2011), available at http://www.fcaalert.c 
om/uploads/file/Qui%20Tam%20Article.pdf (citing decisions by courts in the District of 
Massachusetts and the Eastern District of Pennsylvania to unseal, respectively, 25 and 2 cases 
before the government’s decision on intervention). 
 
95
 Burnett v. New York Cent. R.R. Co., 380 U.S. 424, 428 (1965) (citations omitted). 
 
96






 See, e.g., United States v. Baylor Univ. Med. Ctr., 469 F.3d 263, 268 (2d Cir. 2006) 
(denying relation-back); United States ex rel. Miller v. Bill Harbert Int’l. Const., Inc., Civil 
Action No. 95-1231 (RCL), 2007 WL 851855, at *2 (D.D.C. Mar. 14, 2007) (rejecting Baylor 
holding) (citations omitted); United States ex rel. Sikkenga v. Regence Bluecross Blueshield 
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complaint will relate back to the relator’s complaint so long as the government’s 
complaint arises out of the same conduct, transactions, or occurrences set forth in the 
relator’s complaint.99  Thus, with the relator’s initial complaint serving as a place-
holder for statute of limitations purposes, there is little incentive for the government 
to make its intervention decisions on a timely basis.  There is no simply no 
established mechanism to force the DOJ to “fish or cut bait” in FCA cases.100  
If anything, the FCA’s unregulated seal period encourages government delay.  In 
contrast to non-FCA cases, where defendants will immediately issue document 
requests, interrogatories, and deposition notices while the evidence is fresh, the 
government enjoys an open-ended period of one-sided discovery during the seal 
period.  While the defendant in FCA cases has no ability to serve discovery during 
the seal period, there are no such constraints on plaintiffs.  This provides the plaintiff 
an unparalleled opportunity to build its case while evidence is fresh, including the 
ability to contact key witness and persuade them with their litigation theories.101  
One court disturbed by this state of affairs commented, “the government appears to 
be fully engaged in its discovery, without giving the defendants the opportunity even 
to answer the complaint,” including “criss-crossing the country” doing “investigate 
interviews” with “numerous current and former [defendant] employees and 
government personnel.”102  
An extended seal period might also allow the government to increase its 
damages.  For example, in the AWP litigation the government sought damages 
relating to claims submitted (and paid) for several years after the relator filed its 
initial complaint.103  Generally speaking, a party is not permitted to recover damages 
after it becomes aware of the alleged wrongdoing and has had a reasonable 
                                                          
of Utah, 472 F.3d 702 (10th Cir. 2006) (rejecting argument that FCA action commences when 
government unseals the complaint and files a complaint-in-intervention); United States ex rel. 
Parikh v. Premera Blue Cross, No. CV01-0476 MJP, 2007 WL 1031724, at *3-4 (W.D. Wash. 
Apr. 3, 2007) (holding an FCA action commences, and the statute of limitations is tolled, 
when relator files initial complaint). 
 
99
 31 U.S.C. § 3731(c) (West 2010).  
 
100




 Abbott Laboratories Inc.’sMemorandum inSupport of Its Motion For Partial Summary 
Judgment at 29-30, Dkt. No. 6186, In re Pharm. Indus. Average Wholesale Price Litig., MDL 
1456, Civ. Action No. 01-CV-12257-PBS (D. Mass. June 26, 2009) (In the federal AWP 
litigation, the government’s motions for extension (eventually unsealed after motions practice) 
depict substantial discovery efforts by government investigators during the under seal period.  
These efforts included “pressing defendants to produce responsive documents,” “creating an 
electronic database for storage and review of the thousands of documents,” “shar[ing] . . . 
documents” with Medicaid officials, “conducting witness interviews across the country,” and 
retaining “teams of accounting and data analysis experts.”).   
 
102




 See United States’ Common Memorandum of Law in Support of Cross-Motions from 
Summary Judgement and in Opposition to the Defendants’ Motions for Summary Judgment at 
36-37, Dkt. No. 6440, In re Pharm. Indus. Average Wholesale Price Litig., MDL 1456, Civ. 
Action No. 01-CV-12257-PBS (D. Mass. Aug. 28, 2009). 
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opportunity to stop relying on the alleged wrongdoing.104  But the government might 
argue that it has no obligation to “mitigate” damages under the FCA and that its 
knowledge of the fraud (even by virtue of a filed qui tam complaint) does not 
preclude recovery.105  The mere possibility of continuing treble damages would seem 
not to promote timely action.106  Indeed, in the Community Health Systems litigation, 
the defendants have contended that the government suppressed certain reports “in 
order to create additional damages.” 107 
B.  The Lack of a Clear “Trigger Date” Can Delay Preservation Efforts. 
It is now commonly accepted that “[o]nce a party reasonably anticipates 
litigation, it is obligated to suspend its routine document retention/destruction policy 
and implement a ‘litigation hold’ to ensure the preservation of relevant 
documents.”108  The duty is triggered “not only during litigation,” but also when 
litigation is “reasonably foreseeable.”109  When, exactly, litigation was “reasonably 
                                                          
 
104
 A seminal case on this point is a 1886 case from the Minnesota Supreme Court, which 
held: “[T]o allow a person who has discovered the fraud while the contract is still wholly 
executory to go on and execute it, and then sue for the fraud, looks very much like permitting 
him to speculate upon the fraud of the other party.  It is virtually to allow a man to recover for 
self-inflicted injuries.”  Thompson v. Libby, 31 N.W. 53, 53 (Minn. 1886).  Accord, e.g., Thor 
Power Tool Co. v. Weintraub, 791 F.2d 579, 585 (7th Cir. 1986) (“[g]enerally, a defrauded 
party cannot recover damages for the period after the victim discovers the fraud”); Slotkin v. 
Citizens Cas. Co. of N.Y., 614 F.2d 301, 313 (2d Cir. 1979) (noting that “[t]his rule prevents a 
plaintiff from recovering damages for ‘self inflicted’ injury”); Sanitoy, Inc. v. Shapiro, 705 F. 
Supp. 152, 156 (S.D.N.Y. 1989) (“Many cases have held that if a plaintiff continues to deal 
with a defendant after discovering the truth of the defendant’s misrepresentations, the plaintiff 
waives any fraud claim for damages arising subsequent to the discovery.”).  
 
105
 See supra note 103.   
 
106
 The Supreme Court has recognized the perverse incentives that exist in a situation 
where plaintiff might seek to recover treble damages for ongoing conduct.  In holding that the 
plaintiff in a private antitrust matter could not recover damages after it was aware of the fraud, 
the Court reasoned that to allow otherwise would “permit plaintiffs who know of the defen-
dant’s pattern of activity simply to wait, ‘sleeping on their rights,’ as the pattern continues and 
treble damages accumulate, perhaps bringing suit only long after the ‘memories of witnesses 
have faded or evidence is lost.’” Klehr v. A.O. Smith Corp., 521 U.S. 179, 186-88 (1997) 
(quoting Wilson v. Garcia, 471 U.S. 261, 271 (1985)). 
 
107
 United States ex rel. Baker v. Cmty. Health Sys., Civil No. 05-279 WJ/ACT, 2012 U.S. 
Dist. LEXIS 146865, at *23-24 (D.N.M. Aug. 31, 2012). 
 
108
 Zubulake v. UBS Warburg LLC, 220 F.R.D. 212, 218 (S.D.N.Y. 2003).  Even prior to 
Judge Scheindlen’s landmark opinions in Zubulake, courts generally required parties to take 
affirmative action once a duty to preserve evidence was triggered.  See, e.g., Danis v. USN 
Communications, No. 98C7482, 2000 WL 1694325, at *32 (N.D. Ill. Oct. 23, 2000) (duty to 
preserve must be “discharged actively”); Nat’l Ass’n of Radiation Survivors v. Turnage, 115 
F.R.D. 543, 557-58 (N.D. Cal 1987) (“The obligation to retain discoverable materials is an 
affirmative one; it requires that the agency or corporate officers having notice of discovery 




 Silvestri v. Gen. Motors Corp., 271 F.3d 583, 590-91 (4th Cir. 2001); see also Blinzler 
v. Marriott Int’l, Inc., 81 F.3d 1148, 1159 (1st Cir. 1996); The Sedona Conference, The 
Sedona Conference Commentary on Legal Holds: The Trigger and the Process 5 (2007), 
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foreseeable” depends on the facts of each case, and courts do not always agree on 
even general standards.  Some courts hold litigation must be “probable” or even 
“imminent”—not merely “a possibility”—before the duty to is triggered.110  Other 
courts reject the “probable” standard in favor of the traditional “reasonably 
anticipated” standard.111  Of course, the likelihood of litigation (as opposed to an 
out-of-court resolution) depends on the parties’ respective views of the dispute.  If a 
pre-litigation settlement is unlikely, the duty to preserve  would likely attach at an 
earlier period of time. 
Once a FCA qui tam case is filed by the relator, not only is litigation “reasonably 
anticipated,” some sort of litigation—which the government may seek to relate back 
to for statute of limitations purposes—has actually been filed.  There is some 
precedent suggesting that a relator’s complaint may trigger a duty on the government 
to preserve evidence.  In Miller v. Holzmann, an intervened case relating to bidding 
on waste water treatments in Egypt, Magistrate Facciola found that the government 
spoliated various files relating to its investigation of the alleged misconduct.  
Magistrate Facciola found that “it cannot be seriously argued that [the lost files] did 
not contain information relevant to this case and there was no duty to preserve it 
once relator filed his complaint.”112   
The court in the Community Health Systems litigation also addressed this 
question.  There, the court tersely rejected the government’s claim that its duty to 
preserve did not arise “until the very day” its notice of intervention was filed on 
February 20, 2009.113  The court found that even under the Tenth Circuit’s more 
lenient “imminent” standard, the government had a duty to preserve once the 
defendants had rejected a settlement offer several months earlier.114  The court also 
                                                          




 See Cache La Poudre Feeds, LLC v. Land O'Lakes, Inc., 244 F.R.D. 614, 621 (D. Colo. 
2007) (“While a party should not be permitted to destroy potential evidence after receiving 
unequivocal notice of impending litigation, the duty to preserve relevant documents should 
require more than a mere possibility of litigation.”); Hynix Semiconductor Inc. v. Rambus, 
Inc., 591 F. Supp.2d 1038, 1061-62 (N.D. Cal. 2006) (holding litigation must be “probable,” 
rather than “a possibility,” and the “path to litigation” must be “clear” and “immediate”); 
Henkel Corp. v. Polyglass USA, Inc., 194 F.R.D. 454, 456 (E.D.N.Y. 2000) (finding the duty 
to preserve arises when litigation is “‘likely to be commenced’”) (quoting Turner v. Hudson 
Transit Lines, Inc., 142 F.R.D. 68, 73 (S.D.N.Y. 1991)); Turner v. Public Serv. Co. of Colo., 
563 F.3d 1136, 1149 (10th Cir. 2009) (applying “imminent” standard). 
 
111
 See Goodman v. Praxair Services, Inc., 632 F. Supp.2d 494, 509, n.7 (D. Md. 2009) 
(“This Court declines to follow the Cache ruling, as the law surrounding the duty to preserve 
is well-settled in the Fourth Circuit.”); Samsung Elecs. Co., Ltd. v. Rambus, Inc., 439 F. 
Supp.2d 524, 568 (E.D. Va. 2006) (“[T]he point at which litigation becomes probable does not 
necessarily correspond with when a party anticipated, or reasonably should have anticipated, 
litigation.”), vacated on other grounds, 523 F.3d 1374 (Fed. Cir. 2008), cert. denied, U.S. ----, 
129 S. Ct. 279, 172 L. Ed. 2d 149 (2008). 
 
112
 Miller v. Holzmann, No. 95-01231, 2007 WL 172327, at *3-6 (D.D.C. Jan. 17, 2007). 
 
113
 See United States ex rel. Baker v. Cmty. Health Sys., Civil No. 05-279 WJ/ACT, 2012 
U.S. Dist. LEXIS 146865, at *14-20 (D.N.M. Aug. 31, 2012). 
 
114
 See id. at *17. 
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observed that while the government had earlier instructed the defendants to preserve 
documents, it “did not impose a similar obligation on itself.”115   
Apart from these decisions, however, there is little guidance in written opinions 
on the extent to which a relator’s complaint triggers a duty to preserve evidence.  
Although the government is the “party in interest” in FCA cases where it has not yet 
intervened, that does not necessarily mean courts will consider it a “party” or that the 
government should be deemed to have reasonably anticipated litigation.116  The DOJ 
often determines that the relator’s claims lack merit and declines to intervene.  Many 
declined cases never mature to active litigation, either because the government 
moves to dismiss the case or the relator abandons the claim.117  Other times, the DOJ 
will simultaneously intervene and settle cases before active litigation begins.118  
Because many relator complaints never mature to litigation, a bright-line rule 
triggering a duty to preserve evidence once a relator complaint is filed would appear 
too broad, for both plaintiffs and defendants alike. 
At the same time, imposing no duty on the government to preserve evidence until 
and unless it intervenes can be even more problematic.  The duty to preserve attaches 
once the plaintiff has decided to sue,119 and this duty is usually “triggered before 
litigation commences, in large part because plaintiffs control the timing of 
litigation.”120  Thus, in cases where the government does intervene, an appropriate 
                                                          
 
115
 Id. at *19. 
 
116
 See United States ex rel. Farrell v. SKF USA, Inc., 32 F. Supp.2d 617, 618 (W.D.N.Y. 
1999) (“If the United States remains a party to every qui tam action, Congress’s intent in 
creating the option provision would be thwarted since the government counsel would have to 
expend government resources to respond to discovery requests from hundreds of private 
suits.”); United States ex rel. Sanders v. Allison Engine Co., 364 F. Supp.2d 716, 719 (citing 
Farrell in holding, “[y]et, because it is not a party to the action, the Government is not bound 
by the Federal Rules of Civil Procedure as they relate to discovery”); CLAIRE M. SYLVIA, THE 
FALSE CLAIMS ACT: FRAUD AGAINST THE GOVERNMENT § 11:113 (West 2012) (“When the 
Government declines to intervene in a case, although it remains real party in interest, it is not a 




 See United States Dep’t of Justice, False Claims Act Cases: Govt. Intervention in Qui 
Tam (Whistleblower) Suits 2, available at http://www.justice.gov/usao/pae/Civil_Division/ 
InternetWhistleblower%20update.pdf (last visited April 7, 2013) (indicating “[f]ewer than 
25% of filed qui tam actions result in an intervention on any count by the Department of 
Justice,” which includes cases where the government intervenes and simultaneously settles the 
pending qui tam). 
 
118
 See id. 
 
119
 See Samsung Elecs. Co. v. Rambus, Inc., 439 F.Supp. 2d 524, 559 (E.D. Va. 2006) 
(holding plaintiff’s duty to preserve was triggered once it had “identified the most likely and 
attractive litigation targets, and had settled on a number of possible legal theories to press 
against specific targets”); Struthers Patent Corp. v. Nestle Co., 558 F.Supp. 747 (D.N.J. 1981) 
(holding plaintiff improperly spoliated evidence during the time that it was “actively planning 
to institute a complex patent action against Nestle.”). 
 
120
 Pension Comm. of the Univ. of Montreal Pension Plan v. Banc of Am. Sec., LLC, 685 
F.Supp.2d 456, 466 (S.D.N.Y. 2010); Cyntegra, Inc. v. Idexx Labs., Inc., No. 06 Civ. 4170, 
2007 WL 5193736, at *3 (C.D. Cal. Sept. 21, 2007) (stating that because plaintiffs control 
when litigation begins, they “must necessarily anticipate litigation before the complaint is 
filed”); Indemnity Ins. Co. of N. Am. v. Liberty Corp., No. 96 Civ. 6675, 1998 WL 363834, at 
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trigger date probably lies somewhere between the relator’s initial filing and the 
government’s notice of intervention.  But short of mind-reading or some admission 
by the government, defendants cannot easily learn or prove when the government 
“reasonably anticipated” litigation.  
A prolonged “investigatory” period makes it more difficult, and potentially more 
important, to fix the trigger date. While many of today’s multiple-defendant, 
nationwide FCA actions require more than the standard 60-day investigation, 
undoubtedly something else beyond staffing shortages is driving the excessive 
delays seen in recent years. The quasi-political nature of more recent FCA suits 
probably contributes, as some suits may languish under seal until the right mix of 
prosecutors, regulatory officials, and political and legal environment comes together 
to stimulate an intervention.  The lack of any effective statute of limitations and the 
possibility the government might recover ongoing treble damages would also appear 
to contribute to delay.121 Finally, while some courts have expressed reservations 
about the practice, the possibility of a pre-litigation settlement can delay the 
intervention decision.122     
The federal AWP litigation, concerning drug payments made by both the 
Medicare and Medicaid programs, presents an example of this difficulty.  There, the 
relator filed its initial complaint under seal in 1995.123 More than a decade later, the 
government finally decided to intervene against certain manufacturers—seeking 
damages and penalties not only for alleged claims before the relator’s complaint, but 
also on claims submitted for more than a decade thereafter.124 Despite receiving a 
request by defendants in 2000 to preserve evidence, the government did not institute 
a litigation hold or request to the relevant federal or state agencies and contractors 
until more than a year after it first intervened, resulting in what defendants alleged to 
be a mass spoliation of relevant evidence.125  While it is untenable to suggest that the 
                                                          
*4, n.3 (S.D.N.Y. June 29, 1998) (holding that “the following factors demonstrate that plain-
tiff was on notice that a lawsuit was likely so as to trigger a duty to preserve the evid-ence: (1) 
the sheer magnitude of the losses; (2) that plaintiff attempted to document the damage through 
photographs and reports; and (3) that it immediately brought in counsel as well as experts to 
assess the damage and attempt to ascertain its likely causes in anticipation of litigation”). 
 
121
 See supra text accompanying notes 103-107. 
 
122
 See, e.g., United States ex rel. Costa v. Baker & Taylor, Inc., 955 F.Supp. 1188, 1191 
(N.D. Cal. 1997)  (noting that “one cannot help wondering whether the fact that the defen-
dants must guess about the case filed against them is not the more significant settlement 
advantage currently enjoyed by the government,” that “Congress enacted the seal provision to 
facilitate law enforcement, not to provide an extra bargaining chip in settlement negotiati-
ons.”); See United States v. St. Joseph’s Reg’l Health Ctr., 240 F.Supp.2d 882, 888 (W.D. 
Ark. 2002) (stating multiple interventions by the government seemed designed “to allow the 
government to investigate and settle the multiple claims at its own pace, selectively carving 
out those claims that were easiest to settle while keeping the remaining defendants in limbo 
until it chose to act against them”). 
 
123
 See Abbott Laboratories Inc.’s Memorandum in Support of its Motion For a Finding of 
Spoliation and For Sanctions at 2, Dkt. No. 6097, In re Pharm. Indus. Average Wholesale 
Price Litig., MDL 1456, Civ. Action No. 01-CV-12257-PBS (D. Mass. June 4, 2009).   
 
124
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government did not “reasonably anticipate” litigation until the moment it filed its 
intervention papers eleven years after the relator’s complaint, establishing the 
appropriate trigger date presents a challenging issue. 
Cases where the government declines to intervene, but the relator decides to go 
forward, raise additional issues—including whether the government has a duty to 
preserve evidence and, if so, when.  If the government declines intervention, it 
considers itself a “third party” for discovery purposes and requires that document 
requests be served through a Rule 45 subpoena.126  The duty to preserve evidence 
generally applies to party litigants, not third parties.  Nonetheless, the government 
(as the real party in interest) is plainly not a typical “third party” in such cases.  Its 
agents may be directly involved in the events surrounding the allegations.  Under 
some circumstances, for example in the common situation where the government has 
decided it will either obtain a large settlement from defendants or intervene, some 
duty of preservation should attach to the government.127 
C.  The Scope of the Government’s Duty to Preserve Evidence in False Claims Act 
Cases Can Be Unclear. 
FCA cases can also pose unique questions on the scope of the government’s duty 
to preserve evidence, including how broad the duty extends across federal and state 
government entities.  Generally speaking, a party must generally preserve evidence 
within its “possession, custody, or control,”128 including from the “key players” 
involved in the subject matter of the dispute.  While “possession” and “control” are 
self-explanatory, the parameters of “control” will depend on the nature of the 
relationship between the party and the third party possessing the material, as well as 
the underlying legal standard applied by the court.  Some courts have held that 
“documents are considered to be under a party’s control when that party has “‘the 
right, authority, or practical ability to obtain the documents from a non-party to the 
action.’”129  Under this “practical ability” test, documents are deemed within the 
                                                          
 
126
 See False Claims Act Cases: Government Intervention in Qui Tam (Whistleblower) 
Suits, U.S. DEP’T OF JUSTICE, https://www.doioig.gov/docs/falseclaimsact.pdf (last visited 
April 6, 2013) (“If the United States declines to intervene, the relator and his or her attorney 
may prosecute the action on behalf of the United States, but the United States is not a party to 
the proceedings apart from its right to any recovery.”). 
 
127
 Although no court appears to have addressed the possibility, defendants could argue that 
there is a “special relationship” between the relator and the government in FCA cases that 
triggers a responsibility on the government to preserve evidence. Some states have articulated 
a test for whether there is a duty to preserve evidence. See, e.g., Smith v. Shipping Utilities, 
Inc., No. Civ. 05-500-GPM, 2005 WL 3133494, at *2-3 (S.D. Ill. Nov. 23, 2005) (stating the 
elements of determining whether there is a duty to preserve evidence under Illinois law). 
 
128
 See In re NTL Sec. Litig., 244 F.R.D. 179, 195 (S.D.N.Y. 2007). 
 
129
 Shcherbakovskiy v. Da Capo Al Fine, Ltd., 490 F.3d 130, 138-39 (2d Cir. 2007) (noting 
that a party was entitled to obtain documents if an opposing party “has access to them and can 
produce them”); see also In re Rudolfo Lozano, 392 B.R. 48, 55-56 (Bankr. S.D.N.Y. 2008) 
(noting that there is a practical ability to obtain documents “if the assignee of the original 
mortgagee, or the current loan servicer, can by custom or practice in the mortgage business 
informally request and obtain the original loan file, and any related documents, including a 
payment history”); Ice Corp. v. Hamilton Sundstrand Corp., 245 F.R.D. 513, 521 (D. Kan. 
2007) (noting that defendants had practical ability when they could “simply ask” or “employ 
their ‘right or ability to influence’” so as to gain documents); Steele Software Sys., Corp. v. 
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party’s control if it is able to ask for documents and receive them.130  Other courts 
take a more restrictive view of the scope of a party’s “control.”131  The question 
likely turns on the facts of each case. 
In many of the more novel FCA cases, potentially relevant information affiliated 
with the government might reside outside the federal agency that paid the allegedly 
false claims in question. Additional repositories of relevant information could 
include other government agencies, government contractors, and state agencies.  
There should be little dispute that documents held by federal agencies and their 
government contractors are within the federal government’s “possession, custody, or 
control.”  Similarly, in state FCA actions, documents held by state agencies and their 
contractors are likely within the scope of the state’s duty to preserve evidence.  But 
what about evidence in the possession of the states (or their contractors) that is 
relevant to a federal FCA claim—such as the large (and growing) number of FCA 
claims seeking recovery relating to state Medicaid programs?  Is evidence from these 
“key players” within the federal government’s “control?”  Similar issues could exist 
in state FCA actions for payments made by city or county programs funded by state 
dollars.   
These are not merely hypothetical questions. In the AWP, off-label marketing, 
and intergovernmental transfer FCA actions, evidence from the states is important to 
a host of issues, including whether the claims were false, whether the government 
knowingly permitted or acquiesced in paying the alleged “overpayments,” scienter, 
and damages.132  In the federal AWP litigation, the parties disagreed on whether the 
                                                          
DataQuick Info. Sys., Inc., 237 F.R.D. 561, 564 (D. Md. 2006) (stating that control “has been 
construed broadly by the courts as the legal right, authority, or practical ability to obtain the 
materials sought on demand.”); Synopsys, Inc. v. Ricoh Co., No. C-03-2289 MJJ (EMC), 
2006 WL 1867529, at *2 (N.D. Cal. July 5, 2006) (noting that defendant had practical ability 
to obtain documents because the third party agreed to be represented by defense counsel for 
purposes of discovery and defendant was able to secure a search for documents in third party’s 
facility within three days); In re NTL Sec. Litig , 244 F.R.D. at 195 (quoting Bank of N.Y. v. 
Meridien BIAO Bank Tanzania Ltd., 171 F.R.D. 135, 146-47 (S.D.N.Y. 1997)); Bank of N.Y. 
v. Meridien BIAO Bank Tanzania Ltd., 171 F.R.D. 135, 149 (S.D.N.Y. 1997) (noting that 
defendant had practical ability to obtain documents from third-party because “[the defendant] 
ha[d] been able to obtain documents from [the third-party] when it ha[d] requested them,” and 
the third-party readily cooperated with the defendant’s requests by searching for and turning 
over relevant documents from its files); Golden Trade, S.r.L. v. Lee Apparel Co., 143 F.R.D. 
514, 525 (S.D.N.Y. 1992) (noting that plaintiff had practical ability to obtain documents from 
third party because sub-license agreement provided the plaintiff the “right to cooperation” by 
the third party and prior history of the case suggested such cooperation encompassed 
“production of documents and other assistance in conducting discovery”). 
 
130
 See id; see also David S. May, Third-Party Discovery: Who’s in Control?, 25 NAT. RES. 
& ENV’T 48, 49 (Summer 2010).  
 
131
 See Chaveriat v. Williams Pipe Line Co., 11 F.3d 1420, 1427 (7th Cir. 1993) (“[T]he 
fact that a party could obtain a document if it tried hard enough and maybe if it didn't try hard 
at all does not mean that the document is in its possession, custody, or control; in fact, it 
means the opposite.”); Goodman v. Praxair Services, Inc., 632 F. Supp.2d 494, 514-15; 
Bleecker v. Standard Fire Ins. Co., 130 F. Supp.2d 726, 739 (E.D.N.C. 2000) (“Adopting the 
‘ability to obtain’ test would usurp [the principles of Rule 34], allowing parties to obtain 
documents from non-parties who were in no way controlled by either party.”). 
 
132
 In both the Englund and AWP cases, key CMS officials acknowledged primary 
decision-making on Medicaid program issues rested with the states.  See United States ex rel. 
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federal government had a duty to preserve evidence from the states.  The 
government argued that the states were not “agents” of the federal government and 
that it had no obligation to produce or preserve material “in the possession of other 
sovereigns.”133  Defendants pointed to the joint federal-state nature of Medicaid, the 
federal government’s “common interests agreements” with several states relating to 
drug pricing litigation, the government’s history of successfully requesting 
information from the states during its investigation and prosecution of the case, and 
the fact that the DOJ eventually did ask the states to preserve evidence.134  This, 
defendants argued, demonstrated that the federal government had sufficient control 
and practical ability to obtain the information from the states.135  If nothing else, the 
federal government could—as it did in the Community Health Systems litigation—at 
least “remind” relevant state agencies of their duty to preserve evidence.136 
In non-FCA cases, of course, a party does not have to rely on the opposing party 
to assure the preservation of relevant evidence in the hands of third parties.  It can 
issue subpoenas to produce or at least preserve the evidence.  But in under-seal FCA 
actions, the defendant’s hands are tied; there is no clear mechanism to assure 
evidence from government entities and third parties is retained during what could be 
a lengthy investigation.  The free market of discovery, where a defendant can obtain 
what it believes is important to its defense, simply does not exist. 
                                                          
Englund v. Los Angeles Cnty., No. CIV. S-04282 LKK/JFM, 2006 WL 3097941,, at *4 (E.D. 
Ca. Oct. 31, 2006) (noting that intergovernmental transfers were controversial, but the 
“practice of using the savings in any way the State saw fit was well-known”); Id. at *27 
(citing testimony of former CMS Administrator that “[o]nce [the federal money] was paid for 
services that were actually being provided at that point our sort of formal jurisdiction over it 
and interest of what became of the funds ended”); see also Defendants Abbott Laboratories 
Inc., Dey, Inc., Dey, L.P., Dey L.P., Inc., and Boehringer Ingelheim Roxane, Inc. and Roxane 
Laboratories, Inc.’s Combined Local Rule 56.1 Statement of Additional Material Facts 
Pertinent To the United States’ Motions For Partial Summary Judgment Against Defendants at 
¶ 20, In re Pharm. Indus. Average Wholesale Price Litig., No. 6448, MDL 1456, Civ. Action 
No. 01-CV-12257-PBS (D. Mass. Aug. 30, 2009) (quoting testimony from former CMS 
Administrator that “governors and Medicaid directors have to deal with community 
pharmacists, and local pharmacists, and local politics, and that’s not the role of, in this 
administration, anyway, the role of the CMS administrator to go in and tell states what they 
have to pay”); see also id. at ¶¶ 18-22, 60-64.  
 
133
 See United States’ Sur-Reply in Opposition to Defendants’ Motions For a Finding of 
Spoliation and For Sanctions at 15-16, In re Pharm. Indus. Average Wholesale Price Litig., 
No. 6734, MDL 1456, Civ. Action No. 01-CV-12257-PBS (D. Mass. Dec. 4, 2009). 
 
134
 Abbott Laboratories Inc.’s Response To The United States’ Response To The Court’s 
Instruction Relating To State Medicaid Claims Data at 2-4, In re Pharm. Indus. Average 
Wholesale Price Litig., No. 6924, MDL 1456, Civ. Action No. 01-CV-12257-PBS (D. Mass. 
Feb. 24, 2010).  Because the claims were settled, the issue was never resolved. 
 
135
 See Abbott Laboratories Inc.’s Memorandum in Support of its Motion For a Finding of 
Spoliation and For Sanctions at 9, In re Pharm. Indus. Average Wholesale Price Litig., No. 
6097, MDL 1456, Civ. Action No. 01-CV-12257-PBS (D. Mass. June 4, 2009); see also 
Abbott Laboratories Inc.’s Response To The United States’ Response To The Court’s 
Instruction Relating To State Medicaid Claims Data, supra note 4, at 2-4. 
 
136
 United States ex rel. Baker v. Cmty. Health Sys., Inc., No. 05-279 WJ/ACT, 2012 U.S. 
Dist. LEXIS 146865, at *14 (D.N.M. Aug. 31, 2012). 
2013] THE DARK SIDE OF THE BOOM 211 
 
D.  The Government’s Outdated Position on the Relevance of “Government 
Knowledge” Evidence Can Contribute to Spoliation.  
Another formidable challenge in FCA cases is the government’s frequent 
position on the relevance of evidence from government entities.  The DOJ typically 
advocates an absolutist position, arguing that requests for discovery from 
government entities seeks to support an irrelevant or at least tangentially relevant 
“government knowledge” defense.137  And in the DOJ’s view, only a showing that 
the government formally “approved” of the alleged false claims can defeat 
recovery.138  Under this reasoning, the DOJ argues the government had no duty to 
preserve evidence from the government’s files because they are legally irrelevant.139  
Courts have been hesitant to share the DOJ’s narrow view, particularly before 
discovery can reveal the true relevance of government documents on all facets of the 
FCA claims.  Many decisions have looked to what the government understood in 
deciding whether a claim was “false” or “fraudulent” in the first place.140  And even 
if the government’s mere “knowledge” of a false claim is insufficient to defeat 
claims, courts have held that government “acquiescence” or implicit “approval” can 
defeat claims.141  Courts also recognize that evidence in the government’s files can 
be relevant to issues of causation, materiality, damages, and penalties.142  In the 
federal AWP litigation, for example, the court repeatedly rejected the DOJ’s 
attempts to evade discovery on what it labeled “irrelevant” evidence of “government 
                                                          
 
137
 The government typically argues that its knowledge of a false claim does not defeat a 
FCA claim, and that “government knowledge” evidence can only be relevant to the issue of 
scienter—and then only if the defendant fully disclosed the alleged fraud to the government.  
See, e.g., Cmty. Health Sys., Inc., 2012 U.S. Dist. LEXIS 146865, at *37-38 (“According to 
the Government, its own knowledge is irrelevant and Defendants are incorrectly calling their 
defense a ‘government knowledge inference,’ when in fact it should be called a ‘full disclo-
sure inference.’  The Government contends the burden is on Defendants to prove full disclo-
sure on their part and that what the Government knew at any particular time frame is simply 
not relevant to the litigation.”); United States Common Memorandum of Law in Support of 
Cross-Motions for Partial Summary Judgment and in Opposition to the Defendants’ Motions 
for Summary Judgment at 30-37, In re Pharm. Indus. Average Wholesale Price Litig., No. 
6303, MDL 1456, Civ. Action No. 01-CV-12257-PBS (D. Mass. July 24, 2009).  
 
138
 See supra text accompanying note 137. 
 
139
 See United States’ Memorandum in Opposition to Defendants’ Motions for a Finding of 
Spoliation and for Sanctions at 4-10, Dkt. No. 6270, In re Pharm. Indus. Average Wholesale 
Price Litig., MDL 1456, Civ. Action No. 01-CV-12257-PBS (July 20, 2009). 
 
140
 See United States ex rel. Morton vs. A Plus Benefits, Inc., 139 Fed. Appx. 980, 982-83 
(10th Cir. 2005); United States v. Southland Mgmt. Corp., 326 F.3d 669, 682 (5th Cir. 2003); 
Massachusetts v. Mylan, 608 F. Supp. 2d 127, 148 (D. Mass. 2008); BOESE, supra note 28 at 




 See United States ex rel. Englund v. Los Angeles Cnty., No. CIV. S-04282 LKK/JFM, 
2006 WL 3097941, 2006 U.S. Dist. LEXIS 82034, at *37 (E.D. Ca. Oct. 31, 2006) (granting 
summary judgment for defendants because “the Federal government knew what [defendant] 
was doing and implicitly approved of [defendant’s] actions”) (emphasis added); Mylan, 608 F. 
Supp. 2d at 152 (indicating government knowledge might be relevant to extent state continued 
to use reported prices “as a policy matter”). 
 
142
 See cases cited supra note 32.  
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knowledge,” permitting defendants to take discovery from both state and federal 
officials.143  State courts considering AWP actions have likewise largely rejected 
efforts to stymie the discovery and trial use of evidence from government entities.144   
The court in the Community Health Systems litigation provided particularly 
pointed comments in rejecting the government’s view.  Citing a prior refusal to 
strike the defense of government knowledge, the court noted that “[t]he problem 
with the Government’s view is that it is entirely one-sided.  . . . The bottom line is 
one party’s unilateral and arbitrary determination of relevance cannot dictate the 
timing or the boundaries of the litigation hold.”145   
V.  RECOMMENDATIONS 
As relators and government counsel press new theories of FCA liability to 
challenge sensitive issues of government policy, evidence of what responsible 
governmental officials expected, understood, and accepted surrounding the events in 
question becomes increasingly important.  The duty to preserve evidence in FCA 
litigation, however, has not kept pace with this reality.  Courts routinely grant the 
government’s motions to extend the seal (often for years) without addressing what is 
normally a threshold issue in any litigation—the duty to preserve evidence.146  
Government counsel do not appear to recognize any duty to preserve evidence while 
its investigation languishes under seal.147  Meanwhile, defendants have no effective 
way to assure relevant evidence from government entities and relevant third parties 
is preserved.  The result can be the rampant, prejudicial spoliation of evidence in 
cases seeking treble damages and substantial penalties.   
There are, however, steps that the courts and parties can and should consider in 
an effort to mitigate this escalating problem. 
A.  Increased Court Attention to Spoliation Issues in FCA Actions   
Perhaps most importantly, courts should appreciate that many of today’s FCA 
allegations involve “gray areas” between what is “false or fraudulent” conduct by a 
defendant and what is arguably imperfect government reimbursement policy.  In 
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 See, e.g., supra note 24; Order Re:  Submitted Documents for In Camera Review at 2, 
15, In re Pharm. Indus. Average Wholesale Price Litig., No. 5665, MDL 1456, Civ. Action 
No. 01-CV-12257-PBS (D. Mass. Nov. 5, 2008) (holding that the government’s argument that 
“government knowledge is not a defense to a False Claims Act charge” was “premature” 
because defendant “has the right during discovery to see documents reflecting the 
government’s knowledge about spreads in order to mount the defense”).  
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 See supra text accompanying note 48. 
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 United States ex rel. Baker v. Cmty. Health Sys., Inc., Civil No. 05-279 WJ/ACT, 2012 
U.S. Dist. LEXIS 146865, at *40 (D. N.M. Aug. 31, 2012) (quoting Goodman v. Praxair 
Services, Inc., 632 F. Supp.2d 494 (D. Md. 2009) (“The argument of an accused spoliator that 
it did not violate its duty to preserve evidence because it retained the ‘relevant’ information 
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these cases, defendants will predictably argue that responsible government officials 
were well aware of the alleged wrongdoing and knowingly accepted or acquiesced in 
what is now claimed to be a “false” claim.  Defendants will need government 
documents to prove their defense.   
Instead of rubber-stamping the government’s motions to extend the seal period, 
courts should consider the Congressional intention that the government “should not, 
in any way, be allowed to unnecessarily delay lifting of the seal from the civil 
complaint or processing of the qui tam litigation.”148  Courts should take notice of 
the lessons from one court, which “note[d] with regret that when the earlier 
extensions were granted in this case, the effects of inertia and the lack of an 
opposing party may have resulted in a less searching inquiry regarding good cause 
than is appropriate.”149  Merely requiring the government to make its intervention 
decision in a timely manner would significantly curtail the risk of spoliation.  
Alternatively, courts could follow the recent practice of some judges in the Districts 
of Massachusetts and the Eastern District of Pennsylvania and unseal the relator’s 
complaint when the government unreasonably delays its decision on intervention.150 
Moreover, in those cases where the government’s investigation drags on for 
years, courts should make clear that the government cannot “speculate upon the 
fraud of the other party” and recover damages well after it discovers the alleged 
fraud.151  This would mitigate any perverse incentive for the government to keep 
cases under seal, and encourage timely intervention before evidence is lost.  It would 
also allow courts to timely resolve hotly disputed issues of law—such as the proper 
interpretation of a statute or regulation—thereby avoiding alleged continuing 
damages in the first place.  Courts should also remember that sealed complaints were 
not intended “to affect defendants’ rights in any way.”152  This includes the right to 
have disputed issues of law decided within a reasonable period of time and with a 
reasonably complete factual record.  Allowing cases that turn on a disputed 
interpretation of a government regulation—as many modern FCA cases do—to 
remain under seal for years is neither good policy nor sound law.  
Even in those cases with a prolonged government investigation, courts can take 
steps to encourage the preservation of evidence.  When government counsel appears 
before the court on its motions to extend the seal, the court should inquire about the 
chances that FCA allegations will be litigated.  Once litigation is reasonably 
anticipated, the court should ask government counsel what material from its files 
might be relevant and what steps have been taken to preserve that evidence.  At the 
same time, courts should be skeptical of broad-brushed claims that restrict the “legal 
relevance” of “government knowledge” evidence, including attempts to narrow the 
disputed issues of material fact to avoid evidence of government polices inconsistent 
with plaintiff’s theories.153  If the issues are not clear to the court, it should consider 
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addressing preservation issues with the defendant (who is often made aware, through 
a partial unsealing approved by the court, of a FCA investigation before it is 
unsealed).  These steps are consistent with the guidance provided by the Federal 
Judicial Center’s Manual for Complex Litigation.154  If there is a dispute as to the 
relevance of government evidence, that dispute should be decided by the court 
before evidence is lost, not years later in connection with a spoliation motion.   
In evaluating the potential consequences of a long seal period, courts—and 
perhaps legislators—might consider provisions contained in the Private Securities 
Litigation Reform Act of 1995 (PSLRA).  The PSLRA grants an automatic stay of 
discovery in all private securities actions during the pendency of a motion to 
dismiss.155  “At the same time, Congress included a preservation provision in the 
PSLRA “in recognition that ‘the imposition of a stay of discovery may increase the 
likelihood that relevant evidence may be lost.”’156  The same is true in FCA cases 
and similar safeguards should be implemented.  
Courts should also help assure that efforts to preserve evidence are extended to 
the “key players,” including, where appropriate, state Medicaid agencies.  If the 
federal government is able to gain information from the states during its 
investigation, fairness dictates that courts should similarly require the federal 
government to, at least, request that states preserve relevant evidence.  If it is unclear 
whether the federal government can require states to preserve evidence, courts 
should use their inherent power to regulate and maintain the integrity of their 
proceedings and order—or have the federal government order—preservation by the 
states.157      
Finally, in those cases where the government has failed to satisfy its obligation to 
preserve evidence, courts should not hesitate to subject the government to the same 
variety of spoliation sanctions typically imposed on party litigants.158  When faced 
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with spoliation challenges, courts should critically evaluate when the government 
reasonably anticipated litigation and demand explanations in cases that remained 
under seal for years.  Defendants should not be prejudiced when potentially 
favorable evidence is lost because the government unnecessarily delayed its 
intervention decision.  While the FCA has undoubtedly discouraged fraud and 
restored ill-begotten funds, courts should remember that severe damages and 
penalties make a full and fair evidentiary record especially important in FCA actions. 
In deciding what sanctions may be appropriate, the court should, as in all cases, 
attempt to “(1) deter parties from engaging in spoliation; (2) place the risk of an 
erroneous judgment on the party who wrongfully created the risk; and (3) restore 
‘the prejudiced party to the same position he would have been in absent the wrongful 
destruction of evidence.’”159  Courts should be flexible in fashioning sanctions to 
meet these remedial goals.  For example, if the government did not live up to its 
obligation to preserve evidence while the case remained under seal, an appropriate 
remedy might be to disallow relation-back to the earlier complaint.  Another 
possibility, imposed by the court in the Community Health Systems litigation, is to 
override the government’s right to withhold otherwise available documents withheld 
under the deliberative process, attorney-client privilege, or the work-product 
doctrine.160  Moreover, if the government is better positioned to explain what 
evidence has been lost, courts should demand an accounting from the government.161  
Courts should not hesitate to issue jury instructions on spoliation or shift the burden 
of proof on an issue.  Defendants should not have the burden of disproving an 
element of plaintiffs’ claims or proving a defense that relies on evidence rendered 
incomplete by the government’s spoliation.    
B.  Improved Guidance for Government Attorneys 
The author is not aware of any present guidance to government counsel related to 
the preservation of evidence in government files during the pendency of an FCA 
investigation.  In typical litigation, the parties raise and settle document preservation 
issues early on, often without court guidance.  But this dynamic does not exist during 
FCA investigations, particularly since so many cases settle before the government 
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instigates litigation.  As relators and prosecutors increase their focus on cases where 
the illegality or wrongfulness of the alleged conduct is less clear, one would expect 
that more cases will advance toward full-blown litigation.  Government counsel will 
thus need to be more cognizant of the need to preserve evidence during a prolonged 
investigation.  
An overarching issue is the government’s position on the relevance of 
“government knowledge” evidence in a FCA case.  Government counsel should 
accept that—particularly in those cases that raise issues of government policy—
evidence from the files of government entities might well be relevant to liability and 
damage issues.  If it is unclear what materials the defendant believes are relevant, 
government counsel should discuss those issues with the court or defense counsel, 
not just assume the court will agree with post-hoc arguments on relevance.  If there 
is a dispute over the relevance of government evidence, that dispute should be raised 
at the outset of the litigation and decided by the court. 
Furthermore, because many large FCA cases involve the Medicaid program, 
government counsel should fairly consider how documents from state and perhaps 
local agencies can be preserved.  When evidence from state programs is relevant to a 
nationwide FCA case, government counsel should make efforts to inform their state 
counterparts of the need to preserve evidence once litigation is reasonably 
anticipated.  Government counsel can confer with the court about the most effective 
way to preserve evidence that is not in its direct possession, custody, or control.  The 
government should not wait until the case is unsealed—perhaps many years later—
before making that request.  
C.  Defendants Should Actively Seek to Protect The Preservation of Evidence 
Although a defendant facing an FCA investigation lacks ordinary discovery 
measures, there are steps it can take in an effort to preserve relevant evidence (or at 
least improve its position in a later spoliation challenge).  In non-FCA litigation, a 
party typically learns—to the extent it does not already know—the types of 
documents that need to be preserved in connection with document requests.162  
While an FCA defendant cannot issue formal document requests during an FCA 
investigation, it can advise government counsel, once it becomes aware of an under-
seal qui tam, the types of government evidence it considers relevant.  Thus, once the 
defendant believes litigation is likely with either the relator, the government, or both, 
it should consider making a formal written request to government counsel to 
preserve evidence.163  Defense counsel, of course, must strike a delicate balance 
here, as making demands on the government could adversely affect the 
                                                          
 
162
 Telecom Int’l Am., Ltd. v. AT&T Corp., 189 F.R.D. 76, 81 (S.D.N.Y. 1999) (“Clearly, 
a party is also put on notice when an opponent has made a specific document request.”) 
 
163
 Many courts have considered requests by opposing parties to preserve evidence in 
deciding when the duty to preserve was triggered.  See, e.g., Optowave Co. v. Nikitin, No. 
6:05-cv-1083-Orl-22DAB, 2006 WL 3231422, at *10-11 (M.D. Fla. Nov. 7, 2006) (request by 
opposing party gave “explicit notice of the duty to preserve”); see Wiginton v. CB Richard 
Ellis, 229 F.R.D. 568 (N.D. Ill. 2004) (letter to opposing counsel alerted it to the types of 
electronic information likely to be requested in discovery); cf. In re Tyco Int’l Ltd. Sec. Litig., 
2000 WL 33654141, at *2 (finding defendant aware of documents plaintiff believed should be 
preserved by virtue of parties’ discussions); Clark Constr. Grp., Inc. v. City of Memphis, 229 
F.R.D. 131, 136 (W.D. Tenn. 2005) (“The trigger date is the date a party is put on notice that 
it has a duty to preserve evidence.”). 
2013] THE DARK SIDE OF THE BOOM 217 
 
government’s decision on intervention.  Ideally, defendants should not be placed in 
this position.   
If defense counsel does request the government to take action to preserve 
evidence, counsel should target specific categories of documents from an identified 
list of “key players” to the extent possible.  The government is more likely to 
respond to targeted and manageable requests—and the loss of documents 
specifically targeted by defendants would be more difficult for the government to 
defend.  Defense counsel should engage in a dialogue with government counsel to 
efficiently identify and preserve relevant material.  Furthermore, counsel would be 
well advised to follow-up with the government to understand what efforts, if any, it 
has taken in response to the defendant’s requests. If the government refuses to retain 
material the defendant believes is clearly relevant, defense counsel should consider 
bringing the issue to the court.  Courts have the inherent power to require even third 
parties to preserve evidence.164  If counsel chooses this path, it should obviously be 
prepared to address why particular documents should be preserved and the resulting 
burden on the government.165 
Once the government has made its decision to intervene, the statutory seal no 
longer protects pleadings filed by the relator or the government while the case was 
under seal.166 Even though the government routinely rejects requests to unseal its 
prior filings in FCA actions after the case is unsealed, courts have generally 
“considered lifting the seal on the entire record to be appropriate.”167  Because those 
filings may provide, among other things, information pertinent to when the 
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government reasonably anticipated litigation—and thus had a duty to preserve 
evidence—defense counsel should seek access to the filings under seal.  By 
describing the government’s investigatory efforts, these filings may also help 
defendants contrast the government’s efforts to build its case with a failure to 
preserve evidence relevant to the defense.   
There can be no dispute that the FCA has deterred fraud on the government and 
recouped millions from unscrupulous defendants. At the same time, relators and 
government counsel have aggressively expanded the FCA into situations where 
evidence from government entities becomes necessary for full and fair adjudications.  
Unless efforts to improve the retention of that evidence is improved, judges and 
juries will increasingly find themselves without the information they need to fairly 
resolve FCA disputes. Justice requires a fair playing field in litigating cases under 
this powerful act. 
 
